GSK Clinical Study Register

Size: px
Start display at page:

Download "GSK Clinical Study Register"

Transcription

1 In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The following guiding principles have been applied to the disclosure: Information will be excluded in order to protect the privacy of patients and all named persons associated with the study Patient data listings will be completely removed* to protect patient privacy. Anonymized data from each patient may be made available subject to an approved research proposal. For further information please see the Patient Level Data section of the GSK Clinical Study Register. Aggregate data will be included; with any direct reference to individual patients excluded *Complete removal of patient data listings may mean that page numbers are no longer consecutively numbered

2 Stiefel, a GSK company MaxClarity Clinical Study Report U AN OPEN LABEL, 12 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE MAXCLARITY SYSTEM (BENZOYL PEROXIDE 2.5%, SALICYLIC ACID 0.5%) IN SUBJECTS WITH ACNE CLINICAL STUDY REPORT U VERSION May 2012 Sponsored by: Stiefel, a GSK company 20 TW Alexander Drive Research Triangle Park North Carolina, Conducted by: Stiefel, a GSK company 20 TW Alexander Drive Research Triangle Park North Carolina, THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE LICENSING AND/OR REGISTRATION OF PRODUCTS FOR STIEFEL OR ITS AFFILIATED COMPANIES. THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN WHOLE OR IN PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF STIEFEL. STIEFEL CONFIDENTIAL Page 1

3 Stiefel, a GSK company MaxClarity Clinical Study Report U TITLE PAGE An Open Label, 12 Week Study to Evaluate the Efficacy and Safety of the MaxClarity System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne Name of Investigational Product Indication Description MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA). Acne Open Label, 12-week efficacy and safety evaluation of the MaxClarity System in facial acne. Stiefel, a GSK company Sponsor Protocol/Study Number U Development Phase Consumer Health Non-Prescription Post-Launch Study Study Initiation Date 23 June 2011 Study Completion Date 14 December 2011 Sponsor s Responsible MD Medical Officer Consultant Stiefel, a GSK company Responsible Signatory MD Consultant Stiefel, a GSK company Date of the report 22 May 2012 This study was performed in accordance with Good Clinical Practices, including guidelines outlined by the International Conference on Harmonisation. STIEFEL CONFIDENTIAL Page 2

4 Stiefel, a GSK company MaxClarity Clinical Study Report U SYNOPSIS NAME OF SPONSOR/COMPANY: Stiefel, a GSK company NAME OF FINISHED PRODUCT: MaxClarity System: MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA) NAME OF ACTIVE INGREDIENT(S): 2.5% benzoyl peroxide, 0.5% salicylic acid INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Not applicable Page: Not applicable (FOR NATIONAL AUTHORITY USE ONLY) Title of study: An Open Label, 12 Week Study to Evaluate the Efficacy and Safety of the MaxClarity System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne. Investigators: MD MD MD MD MD MD MD MD MD Publication (reference): No publications related to this study were published as of the date of this report. Study initiation/completion dates: The first subject was enrolled on 23 June 2011 and the last subject completed on 14 December Phase of Development: n/a Objectives: The primary objective was to assess the efficacy of the MaxClarity System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%), which includes MaxClarity Foam Deep Cleanser (2.5% BPO) and MaxClarity Foam Advanced Acne Treatment (2.5% BPO) and MaxClarity Foam Rejuvenating Toner (0.5% SA), in the treatment of moderate to severe acne. The secondary objective was to evaluate the safety and subject satisfaction of this treatment regimen. Methodology: This was a multi-center, open label, safety and efficacy study. One-hundred twenty (120) male/female subjects, 12 to 35 years of age, were to be enrolled into this study. The study duration is 12 weeks (84 days) with study visits occurring at baseline (day 1), week 1, week 2, week 4, week 8, and week 12. Number of subjects (planned and analyzed): 120 subjects planned; 125 enrolled and applied study medication. 115 subjects completed the study and 10 subject discontinued participation prematurely. Diagnosis and Main Criteria for Inclusion: - Capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed. - Male or female ages 12 to 35 years, inclusive, at time of consent. - Investigator s Static Global Assessment (ISGA) score of 3 or 4 at Baseline. - Lesion counts meeting all of the following criteria: A minimum of 25 but not more than 50 facial inflammatory lesions (papules and pustules), excluding nasal lesions. A minimum of 20 but not more than 100 facial noninflammatory lesions (open and closed comedones) on the face, excluding nasal lesions. No more than 3 facial nodular lesions (<5 mm), with no cystic lesions. STIEFEL CONFIDENTIAL Page 3

5 Stiefel, a GSK company MaxClarity Clinical Study Report U NAME OF SPONSOR/COMPANY: Stiefel, a GSK company NAME OF FINISHED PRODUCT: MaxClarity System: MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA) NAME OF ACTIVE INGREDIENT(S): 2.5% benzoyl peroxide, 0.5% salicylic acid INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Not applicable Page: Not applicable (FOR NATIONAL AUTHORITY USE ONLY) - Able and willing to follow all study procedures, attend all visits, and successfully complete the study. - Female subjects of childbearing potential (CBP) required a negative pregnancy test. Sexually active women of CBP participating in the study must have been using a medically acceptable method of contraception. Duration of Study: 12 weeks. Test Product, Dose and Mode of Administration, Batch No.: Max Clarity Foam Deep Cleanser (2.5% BPO; Lot D0J567). Max Clarity Foam Advanced Acne Treatment (2.5% BPO; Lot D0J589). Max Clarity Foam Rejuvenating Toner (0.5% SA; Lot D0J571). AM regimen (wash face with Foam Deep Cleanser, pat dry, apply thin layer of Foam Advanced Acne Treatment); PM regimen (wash face with Foam Deep Cleanser, pat dry, apply Foam Rejuvenating Toner). Criteria for Evaluation: Efficacy: Primary endpoints: - Mean percent change from baseline in inflammatory, non-inflammatory and total lesion counts at each study visit. - Proportion of subjects with a minimum 2-grade improvement in ISGA from Baseline to each study visit. - Proportion of subjects with an ISGA score of 0 (clear) or 1 (almost clear) at each study visit. Secondary endpoints: - Absolute change in inflammatory, non-inflammatory and total lesion counts from Baseline to each study visit. - Mean change in ISGA from Baseline to each study visit. - Post-Inflammatory Hyper pigmentation (Overall Severity) at each study visit. - Post-Inflammatory Hyper pigmentation (Distribution of PIH; % of face affected) at each study visit. - Subject Global Improvement Scale. Patient Preference: - Subject Preference Post-Study Questionnaire. Safety: - Adverse Event reporting. - Concomitant medication use. Statistical Methods: All statistical analyses were performed on the intent-to-treat (ITT) analysis set using SAS software (version 9.2). The ITT analysis set included data from all subjects that were enrolled into the study. A formal sample size calculation was not conducted. No formal statistical hypothesis was formulated for this study. Data are presented in a descriptive fashion and as reported in the case report form (CRF). No inferential statistical testing was conducted and no estimation of missing data was performed. No particular processing for outliers was performed. Descriptive statistics are used to provide an overview of the efficacy and tolerability and safety results. For categorical parameters, the number and percentage of subjects in each category are presented. The denominator for percentage is based on the number of subjects appropriate for the purpose of analysis. For continuous parameters, descriptive statistics include n (number of subjects), mean, standard deviation (STD), median, and range. No estimation of missing data was performed. Age is calculated in years (1 year = days) from birth date to the first dose date and presented with one decimal. No particular STIEFEL CONFIDENTIAL Page 4

6 Stiefel, a GSK company MaxClarity Clinical Study Report U NAME OF SPONSOR/COMPANY: Stiefel, a GSK company NAME OF FINISHED PRODUCT: MaxClarity System: MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA) NAME OF ACTIVE INGREDIENT(S): 2.5% benzoyl peroxide, 0.5% salicylic acid INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Not applicable Page: Not applicable processing for outliers was performed. Data is presented as reported in the CRF. (FOR NATIONAL AUTHORITY USE ONLY) For the final analysis, Adverse Events (AEs) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA, Version 14.1) by system organ class (SOC) and preferred term. Tables summarizing subject incidence of all AEs, serious AEs, severe AEs, treatment-related AEs, treatment-related serious AEs, and treatment-related severe AEs will be provided. All summaries will include treatment emergent events only. Also for the final analysis, prior and concomitant medications will be coded according to the World Health Organization Drug Dictionary (WHODrug) January Individual subject listings of all data represented on the CRF were produced, but are not included with this report. In general, one listing was produced per CRF domain which was sorted by subject number. Additional listings were prepared to support selected summary tables. Individual subject listings will be provided upon request. SUMMARY CONCLUSIONS Efficacy Results: Primary analyses: Lesion counts: At week 12, clinically significant reductions in all lesion types were seen. Mean ± SD percent reduction from baseline of ± 22.0% in total lesions was noted. Inflammatory lesions appeared more responsive than noninflammatory lesions to study product. At week 12, reductions from baseline in inflammatory and noninflammatory lesions were ± 22.7% and ± 25.8%, respectively. At weeks 1, 2, 4 and 8, clinically significant reductions from baseline were noted with all lesion outcomes (see Table 1 below and Section 5.2.2, Summary Tables 5.1, 5.2 and 5.3). Table 1. Summary of Primary Efficacy Results Lesion Counts Primary Efficacy Outcomes Mean percent change in inflammatory lesion count from baseline to: Mean percent change in noninflammatory lesion count from baseline to: Mean percent change in total lesion count from baseline to: Source: Summary Tables 5.1, 5.2, 5.3, Section MaxClarity II (mean ± SD) week ± 25.8% week ± 26.4% week ± 27.0% week ± 23.7 week ± 22.7 week ± 24.4% week ± 24.4% week ± 30.1% week ± 29.3 week ± 25.8 week ± 20.6% week ± 21.5% week ± 23.6% week ± 23.2 week ± 22.0 STIEFEL CONFIDENTIAL Page 5

7 Stiefel, a GSK company MaxClarity Clinical Study Report U NAME OF SPONSOR/COMPANY: Stiefel, a GSK company NAME OF FINISHED PRODUCT: MaxClarity System: MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA) NAME OF ACTIVE INGREDIENT(S): 2.5% benzoyl peroxide, 0.5% salicylic acid INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Not applicable Page: Not applicable (FOR NATIONAL AUTHORITY USE ONLY) At week 12, the proportion of subjects achieving minimal 2-grade improvement in the ISGA was 25.4% (31/122 subjects) and the proportion of subjects with an IGSA score of 0 (clear) or 1 (almost clear) was 16.4% (20/122 subjects). Improvement in IGSA increased steadily throughout the study (see Table 2 below and Section 5.2.2, Summary Table 6). Table 2. Summary of Primary Efficacy Results ISGA Primary Efficacy Outcomes Proportion of subjects with a >2-grade improvement from Baseline to: Proportion of subjects with a score of 0 (clear) or 1 (almost clear): Source: Summary Table 6, Section MaxClarity II n (%) week 1 3 (2.5%) week 2 6 (5.0%) week 4 12 (10.0%) week 8 19 (16.4%) week (25.4%) week 1 1 (0.8%) week 2 2 (1.7%) week 4 4 (3.3%) week 8 10 (8.6%) week (16.4%) Secondary analyses: Absolute change in lesion counts: At week 12, the mean ± SD change in inflammatory lesions from baseline was ± 8.2 lesions. The mean change in non-inflammatory lesions from baseline was ± 15.3 at week 12. The mean change in total lesions from baseline was ± 19.8 at week 12. At weeks 1, 2, 4 and 8, clinically significant reductions from baseline were noted with all lesion outcomes (see Section 5.2.2, Summary Table 5.1, 5.2 and 5.3). Mean change in ISGA: The mean ± SD change in ISGA from baseline was ± 0.78 at week 12 with steady improvement in IGSA being noted throughout the study (see Section 5.2.2, Summary Table 6). Mean change in Post-Inflammatory Hyperpigmentation: The mean ± SD change from baseline in PIH Overall Severity was ± 0.58 at week 12 (see Section 5.2.2, Summary Table 7.1). The mean change from baseline in PIH Distribution was ± 0.53 at week 12. Reductions in PIH Overall Severity and PIH Distribution were noted throughout the study (see Section 5.2.2, Summary Table 7.2). Subject Global Improvement Scale: The mean ± SD change from baseline in Subject Global Improvement was 2.57 ± 0.98 at week 12 with 85.6% of subjects noting at least mild improvement (see Section 5.2.2, Summary Table 8). Patient Preference Results: In measurements of Subject Preference, 70.5% of subjects indicated that they Agree or Strongly Agree when asked if they were Satisfied with Study Products. Compared to Acne Products Used in Past, 66.9% of subjects indicated that they liked the MaxClarity System the best. Please see Section for the full set of patient preference results. STIEFEL CONFIDENTIAL Page 6

8 Stiefel, a GSK company MaxClarity Clinical Study Report U NAME OF SPONSOR/COMPANY: Stiefel, a GSK company NAME OF FINISHED PRODUCT: MaxClarity System: MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA) NAME OF ACTIVE INGREDIENT(S): 2.5% benzoyl peroxide, 0.5% salicylic acid INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Not applicable Page: Not applicable (FOR NATIONAL AUTHORITY USE ONLY) Safety Results: No treatment-related AE were reported with the used of the study products. One subject was withdrawn from study participation due to the occurrence of non-treatment related adverse events (rash on face). There were no SAEs. Please see Section 5.2.4, for the full set of safety results. Conclusions: Clinically significant reductions in all acne lesion counts at all study visits with the MaxClarity System. MaxClarity was also well tolerated with no treatment-related AEs or SAEs reported. Date of the report: 22 May 2012 Signature: Date: MD Contractor Stiefel, a GSK company STIEFEL CONFIDENTIAL Page 7

9 Stiefel, a GSK company MaxClarity Clinical Study Report U TABLE OF CONTENTS 1 TITLE PAGE SYNOPSIS TABLE OF CONTENTS REFERENCE LIST APPENDICES Safety Evaluation Extent of Exposure Adverse Events Brief Summary of Adverse Events Display of Adverse Events Analysis of Adverse Events Listing of Adverse Events by Subject Deaths, Other Serious Adverse Events, and Other Significant Adverse Events Listing of Deaths, Other SAEs, and Other Significant AEs Narratives of Deaths, Other SAEs, and Certain Other Significant AEs Analysis and Discussion of Deaths, Other SAEs, and Other Significant AEs Clinical Laboratory Evaluation Vital Signs, Physical Findings, and Other Observations Related to Safety Safety Conclusions Tables, Figures and Graphs Referred to but not Included in the Text Subject Disposition and Demographic Data Efficacy Data Patient Preference Data Safety Data Protocol and Protocol Amendments STIEFEL CONFIDENTIAL Page 8

10 Stiefel, a GSK company MaxClarity Clinical Study Report U REFERENCE LIST No references cited. STIEFEL CONFIDENTIAL Page 9

11 Stiefel, a GSK company MaxClarity Clinical Study Report U APPENDICES 5.1 Safety Evaluation Extent of Exposure A total of 125 subjects consented and were enrolled in this study and were exposed to topical application of the study products. The mean number of days exposed to study products was 82.4 ± 13.9 days (see Section 5.2.1, Summary Table 4). The minimum exposure was 11 days, and the maximum exposure was 106 days Adverse Events (AEs) Brief Summary of Adverse Events A total of 12 subjects (9.6%) reported experiencing at least 1 treatment-emergent AE (see Section 5.2.4, Summary Table 10.1). No subject experienced a treatment-related AE and no serious adverse events (SAE) were reported Display of Adverse Events The most common treatment-emergent AEs were related to the system organ class (SOC) of Infections and Infestations with 7 subjects (5.6%) experiencing such events (see Table 1 below and Section 5.2.4, Summary Table 10.1). STIEFEL CONFIDENTIAL Page 10

12 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 1. Incidence of Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term (ITT Analysis Set) SYSTEM ORGAN CLASS Preferred Term Total (n = 125) N (%) SUBJECTS REPORTING ANY ADVERSE EVENT 12 (9.6%) GASTROINTESTINAL DISORDERS 1 (0.8%) Gastrooesophageal Reflux Disease 1 (0.8%) IMMUNE SYSTEM DISORDERS 1 (0.8%) Seasonal Allergy 1 (0.8%) INFECTIONS AND INFESTATIONS 7 (5.6%) Nasopharyngitis 3 (2.4%) Oral Herpes 2 (1.6%) Pharyngitis Streptococcal 1 (0.8%) Post Procedural Infection 1 (0.8%) Sinusitis 1 (0.8%) Upper Respiratory Tract Infection 1 (0.8%) Vulvovaginal Mycotic Infection 1 (0.8%) INJURY, POISONING AND PROCEDURAL COMPLICATIONS 1 (0.8%) Contusion 1 (0.8%) NERVOUS SYSTEM DISORDERS 1 (0.8%) Burning Sensation 1 (0.8%) REPRODUCTIVE SYSTEM AND BREAST DISORDERS 1 (0.8%) Ovarian Cyst 1 (0.8%) RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS 1 (0.8%) Rhinitis Allergic 1 (0.8%) SKIN AND SUBCUTANEOUS TISSUE DISORDERS 1 (0.8%) Rash 1 (0.8%) Subjects reporting a particular adverse event more than once are counted only once for that adverse event Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 11

13 Stiefel, a GSK company MaxClarity Clinical Study Report U Analysis of Adverse Events Study products were safe and well tolerated with no treatment-related AE being noted Listing of Adverse Events by Subject Listings will be provided upon request Deaths, Other Serious Adverse Events, and Other Significant Adverse Events Listing of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events No deaths, serious adverse events, or other significant adverse events were reported Narratives of Deaths, Other Serious Adverse Events, and Certain Other Significant Adverse Events No deaths, serious adverse events, or other significant adverse events have yet been reported Analysis and Discussion of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events No deaths, serious adverse events, or other significant adverse events have yet been reported Clinical Laboratory Evaluation Clinical laboratory evaluations were not included as part of study procedures, but may be recorded in support of adverse event diagnosis or follow up Vital Signs, Physical Findings, and Other Observations Related to Safety Vital signs and physical examinations were not recorded as part of study procedures, but may be recorded in support of adverse event diagnosis or follow up Safety Conclusions MaxClarity was well tolerated with no treatment-related AEs or SAEs reported during the study. STIEFEL CONFIDENTIAL Page 12

14 Stiefel, a GSK company MaxClarity Clinical Study Report U Tables, Figures and Graphs Referred to but not Included in the Text Subject Disposition and Demographic Data Table Number Table 1 Table 2 Table 3 Table 4 Table Title Subject Disposition - ITT Analysis Set Demographics - ITT Analysis Set Baseline Disease Characteristics - ITT Analysis Set Treatment Duration ITT Analysis Set STIEFEL CONFIDENTIAL Page 13

15 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 1: Subject Disposition ITT Analysis Set Subject Disposition MaxClarity (n = 125) N (%) Completed 115 (92.0%) Discontinued 10 (8.0%) Reasons for Discontinuation FSI = 23JUN2011; LSI = 14SEP2011; LSO = 14DEC2011 Output: U Table 1.rtf Program: U Table 1.sas Source: Datasets DS and SV Adverse Event 1 (10.0%) Lost to Follow Up 2 (20.0%) Withdrawal of Consent 7 (70.0%) STIEFEL CONFIDENTIAL Page 14

16 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 2: Demographics ITT Analysis Set MaxClarity (n = 125) Age (years) N 125 Mean ± SD 19.0 ± 5.7 Median (P25, P75) 16.9 (15.1, 20.8) Min, Max 12.1, 35.7 Sex, n (%) Male 57 (45.6%) Female 68 (54.4%) Race, n (%) American Indian or Alaskan Native 7 (5.6%) Asian 9 (7.2%) Black 21 (16.8%) Native Hawaiian or Other Pacific Islander 1 (0.8%) White 84 (67.2%) Other 3 (2.4%) Ethnicity, n (%) Hispanic or Latino 27 (21.6%) Not Hispanic or Latino 98 (78.4%) Output: U Table 2.rtf Program: U Table 2.sas Source: Dataset DM STIEFEL CONFIDENTIAL Page 15

17 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 3: Baseline Disease Characteristics ITT Analysis Set Investigator Static Global Assessment, n (%) MaxClarity (n = 125) 3- Moderate 84 (67.2%) 4- Severe 41 (32.8%) Inflammatory Lesion Count N 125 Mean ± SD 32.2 ± 6.7 Median (P25, P75) 29.0 (27.0, 37.0) Min, Max 25.0, 50.0 Non-Inflammatory Lesion Count N 125 Mean ± SD 46.5 ± 21.0 Median (P25, P75) 41.0 (28.0, 58.0) Min, Max 21.0, 97.0 Total Lesion Count N 125 Mean ± SD 78.7 ± 24.5 Median (P25, P75) 75.0 (57.0, 92.0) Min, Max 47.0, Post-Inflammatory Hyperpigmentation Severity, n (%) 0- Absent 51 (40.8%) 1- Slight 15 (12.0%) 2- Mild 41 (32.8%) 3- Moderate 17 (13.6%) 4- Moderately Severe 1 (0.8%) Post-Inflammatory Hyperpigmentation Distribution, n (%) 0- None 54 (43.2%) % of the face 27 (21.6%) % of the face 32 (25.6%) % of the face 11 (8.8%) % of the face 1 (0.8%) Output: U Table 3.rtf Program: U Table 3.sas Source: Dataset EF_BSL STIEFEL CONFIDENTIAL Page 16

18 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 4: Study Product Exposure ITT Analysis Set Treatment duration (days) 1 MaxClarity (n = 125) N 124 Mean ± SD 82.4 ± 13.9 Median (P25, P75) 85.0 (84.0, 86.0) Min, Max 11.0, Missing values 1 Treatment duration (categories), n (%) >=4 weeks 120 (96.8%) >=8 weeks 119 (96.0%) >=12 weeks 99 (79.8%) 1 Time (in days) between first and last treatment applications + 1 Output: U Table 4.rtf Program: U Table 4.sas Source: Dataset MD STIEFEL CONFIDENTIAL Page 17

19 Stiefel, a GSK company MaxClarity Clinical Study Report U Efficacy Data Table Number Table 5.1 Table 5.2 Table 5.3 Table 6 Table 7.1 Table 7.2 Table 8 Table Title Lesion Counts Inflammatory Lesions ITT Analysis Set Lesion Counts Non-Inflammatory Lesions ITT Analysis Set Lesion Counts Total Lesions ITT Analysis Set Investigator Static Global Assessment ITT Analysis Set Post-Inflammatory Hyperpigmentation Assessments Severity ITT Analysis Set Post-Inflammatory Hyperpigmentation Assessments Distribution ITT Analysis Set Subject s Global Improvement Scale ITT Analysis Set STIEFEL CONFIDENTIAL Page 18

20 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.1: Lesion Counts Inflammatory Lesions ITT Analysis Set Total (n = 125) Baseline (Day 1) N 125 Mean ± SD 32.2 ± 6.7 Median (P25, P75) 29.0 (27.0, 37.0) Min, Max 25.0, 50.0 Week 1 N 120 Mean ± SD 22.6 ± 10.0 Median (P25, P75) 22.0 (17.0, 28.5) Min, Max 0.0, 50.0 Missing values 5 Change from Baseline to Week 1 N 120 Mean ± SD -9.6 ± 8.2 Median (P25, P75) -8.0 (-14.5, -3.0) Min, Max -35.0, 9.0 Missing values 5 % Change from Baseline to Week 1 N 120 Mean ± SD ± 25.8 Median (P25, P75) (-48.1, -11.4) Min, Max , 25.7 Missing values 5 Week 2 N 121 Mean ± SD 18.0 ± 10.0 Median (P25, P75) 17.0 (11.0, 23.0) Min, Max 2.0, 52.0 Missing values 4 Change from Baseline to Week 2 N 121 Mean ± SD ± 8.9 Median (P25, P75) (-20.0, -8.0) Min, Max -41.0, 12.0 Missing values 4 STIEFEL CONFIDENTIAL Page 19

21 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.1: Lesion Counts (Continued) Inflammatory Lesions ITT Analysis Set Total (n = 125) % Change from Baseline to Week 2 N 121 Mean ± SD ± 26.4 Median (P25, P75) (-64.4, -25.9) Min, Max -93.1, 30.0 Missing values 4 Week 4 N 120 Mean ± SD 15.3 ± 9.8 Median (P25, P75) 14.0 (8.0, 20.0) Min, Max 0.0, 53.0 Missing values 5 Change from Baseline to Week 4 N 120 Mean ± SD ± 9.3 Median (P25, P75) (-23.5, -10.0) Min, Max -47.0, 4.0 Missing values 5 % Change from Baseline to Week 4 N 120 Mean ± SD ± 27.0 Median (P25, P75) (-74.5, -34.3) Min, Max , 11.4 Missing values 5 Week 8 N 116 Mean ± SD 13.4 ± 9.3 Median (P25, P75) 12.0 (6.0, 18.0) Min, Max 0.0, 52.0 Missing values 9 Change from Baseline to Week 8 N 116 Mean ± SD ± 8.0 Median (P25, P75) (-24.0, -14.0) Min, Max -42.0, 4.0 Missing values 9 STIEFEL CONFIDENTIAL Page 20

22 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 5.1: Lesion Counts (Continued) Inflammatory Lesions ITT Analysis Set MaxClarity (n = 125) % Change from Baseline to Week 8 N 116 Mean ± SD ± 23.7 Median (P25, P75) (-79.0, -44.4) Min, Max , 11.4 Missing values 9 Week 12/Early Termination N 122 Mean ± SD 10.9 ± 8.6 Median (P25, P75) 9.0 (5.0, 16.0) Min, Max 0.0, 51.0 Missing values 3 Change from Baseline to Week 12/Early Termination N 122 Mean ± SD ± 8.2 Median (P25, P75) (-26.0, -18.0) Min, Max -45.0, 3.0 Missing values 3 % Change from Baseline to Week 12/Early Termination N 122 Mean ± SD ± 22.7 Median (P25, P75) (-84.4, -55.3) Min, Max , 7.5 Missing values 3 Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS STIEFEL CONFIDENTIAL Page 21

23 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.2: Lesion Counts Non-Inflammatory Lesions ITT Analysis Set Total (n = 125) Baseline (Day 1) N 125 Mean ± SD 46.5 ± 21.0 Median (P25, P75) 41.0 (28.0, 58.0) Min, Max 21.0, 97.0 Week 1 N 120 Mean ± SD 39.0 ± 20.2 Median (P25, P75) 32.0 (25.0, 50.0) Min, Max 13.0, 96.0 Missing values 5 Change from Baseline to Week 1 N 120 Mean ± SD -7.4 ± 12.1 Median (P25, P75) -6.0 (-13.0, 0.0) Min, Max -43.0, 25.0 Missing values 5 % Change from Baseline to Week 1 N 120 Mean ± SD ± 24.4 Median (P25, P75) (-31.0, 0.0) Min, Max -70.9, 78.6 Missing values 5 Week 2 N 121 Mean ± SD 33.0 ± 19.6 Median (P25, P75) 26.0 (20.0, 41.0) Min, Max 5.0, 94.0 Missing values 4 Change from Baseline to Week 2 N 121 Mean ± SD ± 13.5 Median (P25, P75) (-21.0, -5.0) Min, Max -63.0, 18.0 Missing values 4 STIEFEL CONFIDENTIAL Page 22

24 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 5.2: Lesion Counts (Continued) Non-Inflammatory Lesions ITT Analysis Set Total (n = 125) % Change from Baseline to Week 2 N 121 Mean ± SD ± 24.4 Median (P25, P75) (-44.2, -14.6) Min, Max -89.3, 31.8 Missing values 4 Week 4 N 120 Mean ± SD 29.2 ± 18.7 Median (P25, P75) 24.5 (15.0, 38.0) Min, Max 5.0, 95.0 Missing values 5 Change from Baseline to Week 4 N 120 Mean ± SD ± 15.4 Median (P25, P75) (-27.5, -8.5) Min, Max -57.0, 21.0 Missing values 5 % Change from Baseline to Week 4 N 120 Mean ± SD ± 30.1 Median (P25, P75) (-58.4, -21.5) Min, Max -87.8, 51.2 Missing values 5 Week 8 N 116 Mean ± SD 26.5 ± 19.0 Median (P25, P75) 21.0 (13.0, 33.5) Min, Max 3.0, 99.0 Missing values 9 Change from Baseline to Week 8 N 116 Mean ± SD ± 16.3 Median (P25, P75) (-31.5, -10.0) Min, Max -60.0, 41.0 Missing values 9 Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS STIEFEL CONFIDENTIAL Page 23

25 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.2: Lesion Counts (Continued) Non-Inflammatory Lesions ITT Analysis Set MaxClarity (n = 125) % Change from Baseline to Week 8 N 116 Mean ± SD ± 29.3 Median (P25, P75) (-64.6, -30.0) Min, Max -90.6, 70.7 Missing values 9 Week 12/Early Termination N 122 Mean ± SD 21.1 ± 17.5 Median (P25, P75) 14.0 (9.0, 27.0) Min, Max 0.0, 93.0 Missing values 3 Change from Baseline to Week 12/Early Termination N 122 Mean ± SD ± 15.3 Median (P25, P75) (-36.0, -15.0) Min, Max -73.0, 12.0 Missing values 3 % Change from Baseline to Week 12/Early Termination N 122 Mean ± SD ± 25.8 Median (P25, P75) (-76.3, -45.9) Min, Max , 30.0 Missing values 3 STIEFEL CONFIDENTIAL Page 24

26 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.3: Lesion Counts Total Lesions ITT Analysis Set Total (n = 125) Baseline (Day 1) N 125 Mean ± SD 78.7 ± 24.5 Median (P25, P75) 75.0 (57.0, 92.0) Min, Max 47.0, Week 1 N 120 Mean ± SD 61.6 ± 26.8 Median (P25, P75) 54.0 (43.0, 76.0) Min, Max 16.0, Missing values 5 Change from Baseline to Week 1 N 120 Mean ± SD ± 16.6 Median (P25, P75) (-28.0, -5.0) Min, Max -59.0, 25.0 Missing values 5 % Change from Baseline to Week 1 N 120 Mean ± SD ± 20.6 Median (P25, P75) (-35.9, -7.4) Min, Max -73.8, 28.7 Missing values 5 Week 2 N 121 Mean ± SD 50.9 ± 26.1 Median (P25, P75) 45.0 (32.0, 66.0) Min, Max 7.0, Missing values 4 Change from Baseline to Week 2 N 121 Mean ± SD ± 18.8 Median (P25, P75) (-40.0, -15.0) Min, Max , 8.0 Missing values 4 STIEFEL CONFIDENTIAL Page 25

27 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.3: Lesion Counts (Continued) Total Lesions ITT Analysis Set Total (n = 125) % Change from Baseline to Week 2 N 121 Mean ± SD ± 21.5 Median (P25, P75) (-51.5, -21.4) Min, Max -88.4, 9.3 Missing values 4 Week 4 N 120 Mean ± SD 44.4 ± 25.1 Median (P25, P75) 40.0 (25.5, 57.5) Min, Max 8.0, Missing values 5 Change from Baseline to Week 4 N 120 Mean ± SD ± 20.3 Median (P25, P75) (-49.0, -22.5) Min, Max -87.0, 22.0 Missing values 5 % Change from Baseline to Week 4 N 120 Mean ± SD ± 23.6 Median (P25, P75) (-62.4, -28.5) Min, Max -91.6, 25.6 Missing values 5 Week 8 N 116 Mean ± SD 39.8 ± 25.1 Median (P25, P75) 32.5 (20.5, 53.5) Min, Max 6.0, Missing values 9 Change from Baseline to Week 8 N 116 Mean ± SD ± 20.4 Median (P25, P75) (-52.0, -27.5) Min, Max , 33.0 Missing values 9 STIEFEL CONFIDENTIAL Page 26

28 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.3: Lesion Counts (Continued) Total Lesions ITT Analysis Set MaxClarity (n = 125) % Change from Baseline to Week 8 N 116 Mean ± SD ± 23.2 Median (P25, P75) (-68.2, -36.4) Min, Max -89.7, 38.4 Missing values 9 Week 12/Early Termination N 122 Mean ± SD 32.0 ± 23.4 Median (P25, P75) 25.0 (14.0, 41.0) Min, Max 0.0, Missing values 3 Change from Baseline to Week 12/Early Termination N 122 Mean ± SD ± 19.8 Median (P25, P75) (-59.0, -35.0) Min, Max , 1.0 Missing values 3 % Change from Baseline to Week 12/Early Termination N 122 Mean ± SD ± 22.0 Median (P25, P75) (-80.4, -48.2) Min, Max , 1.5 Missing values 3 STIEFEL CONFIDENTIAL Page 27

29 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 6.rtf Program: U Table 6.sas Source: Datasets EF_BSL & EF_VISITS Table 6: Investigator Static Global Assessment ITT Analysis Set Total (n = 125) Baseline (Day 1), n (%) 3- Moderate 84 (67.2%) 4- Severe 41 (32.8%) Mean ± SD 3.33 ± 0.47 Median (P25, P75) 3.00 (3.00, 4.00) Min, Max 3.00, 4.00 Week 1, n (%) 1- Almost Clear 1 (0.8%) 2- Mild 15 (12.5%) 3- Moderate 83 (69.2%) 4- Severe 21 (17.5%) Mean ± SD 3.03 ± 0.58 Median (P25, P75) 3.00 (3.00, 3.00) Min, Max 1.00, 4.00 Missing values 5 ISGA of 0 (Clear) or 1 (Almost Clear), n (%) 1 (0.8%) Change from Baseline to Week 1, n (%) N 120 Mean ± SD ± 0.51 Median (P25, P75) 0.00 (-1.00, 0.00) Min, Max -2.00, 0.00 Missing values 5 At least one-grade improvement, n (%) 32 (26.7%) At least two-grade improvement, n (%) 3 (2.5%) Week 2, n (%) 1- Almost Clear 2 (1.7%) 2- Mild 27 (22.3%) 3- Moderate 77 (63.6%) 4- Severe 15 (12.4%) Mean ± SD 2.87 ± 0.63 Median (P25, P75) 3.00 (3.00, 3.00) Min, Max 1.00, 4.00 Missing values 4 ISGA of 0 (Clear) or 1 (Almost Clear), n (%) 2 (1.7%) STIEFEL CONFIDENTIAL Page 28

30 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 6.rtf Program: U Table 6.sas Source: Datasets EF_BSL & EF_VISITS Table 6: Investigator Static Global Assessment (Continued) ITT Analysis Set Total (n = 125) Change from Baseline to Week 2, n (%) N 121 Mean ± SD ± 0.61 Median (P25, P75) 0.00 (-1.00, 0.00) Min, Max -2.00, 1.00 Missing values 4 At least one-grade improvement, n (%) 50 (41.3%) At least two-grade improvement, n (%) 6 (5.0%) Week 4, n (%) 1- Almost Clear 4 (3.3%) 2- Mild 40 (33.3%) 3- Moderate 65 (54.2%) 4- Severe 11 (9.2%) Mean ± SD 2.69 ± 0.68 Median (P25, P75) 3.00 (2.00, 3.00) Min, Max 1.00, 4.00 Missing values 5 ISGA of 0 (Clear) or 1 (Almost Clear), n (%) 4 (3.3%) Change from Baseline to Week 4, n (%) N 120 Mean ± SD ± 0.69 Median (P25, P75) (-1.00, 0.00) Min, Max -3.00, 0.00 Missing values 5 At least one-grade improvement, n (%) 63 (52.5%) At least two-grade improvement, n (%) 12 (10.0%) Week 8, n (%) 1- Almost Clear 10 (8.6%) 2- Mild 44 (37.9%) 3- Moderate 53 (45.7%) 4- Severe 9 (7.8%) Mean ± SD 2.53 ± 0.76 Median (P25, P75) 3.00 (2.00, 3.00) Min, Max 1.00, 4.00 Missing values 9 ISGA of 0 (Clear) or 1 (Almost Clear), n (%) 10 (8.6%) STIEFEL CONFIDENTIAL Page 29

31 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 6.rtf Program: U Table 6.sas Source: Datasets EF_BSL & EF_VISITS Table 6: Investigator Static Global Assessment (Continued) ITT Analysis Set MaxClarity (n = 125) Change from Baseline to Week 8, n (%) N 116 Mean ± SD ± 0.75 Median (P25, P75) (-1.00, 0.00) Min, Max -3.00, 0.00 Missing values 9 At least one-grade improvement, n (%) 71 (61.2%) At least two-grade improvement, n (%) 19 (16.4%) Week 12, n (%) 0- Clear 1 (0.8%) 1- Almost Clear 19 (15.6%) 2- Mild 55 (45.1%) 3- Moderate 39 (32.0%) 4- Severe 8 (6.6%) Mean ± SD 2.28 ± 0.84 Median (P25, P75) 2.00 (2.00, 3.00) Min, Max 0.00, 4.00 Missing values 3 ISGA of 0 (Clear) or 1 (Almost Clear), n (%) 20 (16.4%) Change from Baseline to Week 12, n (%) N 122 Mean ± SD ± 0.78 Median (P25, P75) (-2.00, -1.00) Min, Max -3.00, 1.00 Missing values 3 At least one-grade improvement, n (%) 94 (77.0%) At least two-grade improvement, n (%) 31 (25.4%) STIEFEL CONFIDENTIAL Page 30

32 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 7.1: Post-Inflammatory Hyperpigmentation Assessments Severity ITT Analysis Set Output: U Table 7.rtf Program: U Table 7.sas Source: Datasets EF_BSL & EF_VISITS Total (n = 125) Baseline (Day 1), n (%) 0- Absent 51 (40.8%) 1- Slight 15 (12.0%) 2- Mild 41 (32.8%) 3- Moderate 17 (13.6%) 4- Moderately Severe 1 (0.8%) Mean ± SD 1.22 ± 1.15 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 4.00 Week 1, n (%) 0- Absent 47 (39.2%) 1- Slight 18 (15.0%) 2- Mild 40 (33.3%) 3- Moderate 15 (12.5%) Mean ± SD 1.19 ± 1.09 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 5 Change from Baseline to Week 1, n (%) N 120 Mean ± SD ± 0.35 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -2.00, 1.00 Missing values 5 Week 2, n (%) 0- Absent 50 (41.3%) 1- Slight 19 (15.7%) 2- Mild 36 (29.8%) 3- Moderate 16 (13.2%) Mean ± SD 1.15 ± 1.11 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 4 Change from Baseline to Week 2, n (%) N 121 Mean ± SD ± 0.58 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -2.00, 3.00 Missing values 4 STIEFEL CONFIDENTIAL Page 31

33 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 7.1: Post-Inflammatory Hyperpigmentation Assessments (Continued) Severity ITT Analysis Set Total (n = 125) Week 4, n (%) 0- Absent 52 (43.3%) 1- Slight 21 (17.5%) 2- Mild 34 (28.3%) 3- Moderate 12 (10.0%) 4- Moderately Severe 1 (0.8%) Mean ± SD 1.08 ± 1.09 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 4.00 Missing values 5 Change from Baseline to Week 4, n (%) N 120 Mean ± SD ± 0.51 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -2.00, 2.00 Missing values 5 Week 8, n (%) 0- Absent 52 (44.8%) 1- Slight 19 (16.4%) 2- Mild 38 (32.8%) 3- Moderate 7 (6.0%) Mean ± SD 1.00 ± 1.01 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 9 Change from Baseline to Week 8, n (%) N 116 Mean ± SD ± 0.55 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -2.00, 2.00 Missing values 9 Week 12, n (%) 0- Absent 56 (45.9%) 1- Slight 27 (22.1%) 2- Mild 33 (27.0%) 3- Moderate 6 (4.9%) Mean ± SD 0.91 ± 0.96 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 3 Output: U Table 7.rtf Program: U Table 7.sas Source: Datasets EF_BSL & EF_VISITS STIEFEL CONFIDENTIAL Page 32

34 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 7.1: Post-Inflammatory Hyperpigmentation Assessments (Continued) Severity ITT Analysis Set Output: U Table 7.rtf Program: U Table 7.sas Source: Datasets EF_BSL & EF_VISITS MaxClarity (n = 125) Change from Baseline to Week 12, n (%) N 122 Mean ± SD ± 0.58 Median (P25, P75) 0.00 (-1.00, 0.00) Min, Max -2.00, 1.00 Missing values 3 STIEFEL CONFIDENTIAL Page 33

35 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 7.2: Post-Inflammatory Hyperpigmentation Assessments Distribution ITT Analysis Set Output: U Table 7.rtf Program: U Table 7.sas Source: Datasets EF_BSL & EF_VISITS Total (n = 125) Baseline (Day 1), n (%) 0- None 54 (43.2%) % of the face 27 (21.6%) % of the face 32 (25.6%) % of the face 11 (8.8%) % of the face 1 (0.8%) Mean ± SD 1.02 ± 1.06 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 4.00 Week 1, n (%) 0- None 51 (42.5%) % of the face 28 (23.3%) % of the face 30 (25.0%) % of the face 11 (9.2%) Mean ± SD 1.01 ± 1.02 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 5 Change from Baseline to Week 1, n (%) N 120 Mean ± SD ± 0.27 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -1.00, 1.00 Missing values 5 Week 2, n (%) 0- None 55 (45.5%) % of the face 26 (21.5%) % of the face 29 (24.0%) % of the face 11 (9.1%) Mean ± SD 0.97 ± 1.03 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 4 Change from Baseline to Week 2, n (%) N 121 Mean ± SD ± 0.32 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -1.00, 1.00 Missing values 4 STIEFEL CONFIDENTIAL Page 34

36 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 7.2: Post-Inflammatory Hyperpigmentation Assessments (Continued) Distribution ITT Analysis Set Output: U Table 7.rtf Program: U Table 7.sas Source: Datasets EF_BSL & EF_VISITS Total (n = 125) Week 4, n (%) 0- None 55 (45.8%) % of the face 31 (25.8%) % of the face 24 (20.0%) % of the face 10 (8.3%) Mean ± SD 0.91 ± 1.00 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 5 Change from Baseline to Week 4, n (%) N 120 Mean ± SD ± 0.38 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -2.00, 1.00 Missing values 5 Week 8, n (%) 0- None 54 (46.6%) % of the face 29 (25.0%) % of the face 26 (22.4%) % of the face 7 (6.0%) Mean ± SD 0.88 ± 0.96 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 9 Change from Baseline to Week 8, n (%) N 116 Mean ± SD ± 0.41 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -2.00, 1.00 Missing values 9 Week 12, n (%) 0- None 58 (47.5%) % of the face 35 (28.7%) % of the face 24 (19.7%) % of the face 5 (4.1%) Mean ± SD 0.80 ± 0.90 Median (P25, P75) 1.00 (0.00, 1.00) Min, Max 0.00, 3.00 Missing values 3 STIEFEL CONFIDENTIAL Page 35

37 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 7.2: Post-Inflammatory Hyperpigmentation Assessments (Continued) Distribution ITT Analysis Set Output: U Table 7.rtf Program: U Table 7.sas Source: Datasets EF_BSL & EF_VISITS MaxClarity (n = 125) Change from Baseline to Week 12, n (%) N 122 Mean ± SD ± 0.53 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -2.00, 1.00 Missing values 3 STIEFEL CONFIDENTIAL Page 36

38 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 8.rtf Program: U Table 8.sas Source: Dataset EF_VISITS Table 8: Subject's Global Improvement Scale ITT Analysis Set Total (n = 125) Week 1, n (%) 0- Worse 8 (6.7%) 1- Same 15 (12.5%) 2- Mild Improvement 76 (63.3%) 3- Obvious Improvement 17 (14.2%) 4- Marked Improvement 4 (3.3%) Mean ± SD 1.95 ± 0.82 Median (P25, P75) 2.00 (2.00, 2.00) Min, Max 0.00, 4.00 Missing values 5 Week 2, n (%) 0- Worse 3 (2.5%) 1- Same 23 (19.0%) 2- Mild Improvement 61 (50.4%) 3- Obvious Improvement 30 (24.8%) 4- Marked Improvement 4 (3.3%) Mean ± SD 2.07 ± 0.82 Median (P25, P75) 2.00 (2.00, 3.00) Min, Max 0.00, 4.00 Missing values 4 Week 4, n (%) 0- Worse 4 (3.3%) 1- Same 11 (9.2%) 2- Mild Improvement 61 (50.8%) 3- Obvious Improvement 36 (30.0%) 4- Marked Improvement 8 (6.7%) Mean ± SD 2.28 ± 0.85 Median (P25, P75) 2.00 (2.00, 3.00) Min, Max 0.00, 4.00 Missing values 5 Week 8, n (%) 0- Worse 5 (4.3%) 1- Same 9 (7.8%) 2- Mild Improvement 51 (44.0%) 3- Obvious Improvement 44 (37.9%) 4- Marked Improvement 7 (6.0%) Mean ± SD 2.34 ± 0.87 Median (P25, P75) 2.00 (2.00, 3.00) Min, Max 0.00, 4.00 Missing values 9 STIEFEL CONFIDENTIAL Page 37

39 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 8.rtf Program: U Table 8.sas Source: Dataset EF_VISITS Table 8: Subject's Global Improvement Scale (Continued) ITT Analysis Set MaxClarity (n = 125) Week 12, n (%) 0- Worse 4 (3.3%) 1- Same 11 (9.0%) 2- Mild Improvement 39 (32.0%) 3- Obvious Improvement 48 (39.3%) 4- Marked Improvement 20 (16.4%) Mean ± SD 2.57 ± 0.98 Median (P25, P75) 3.00 (2.00, 3.00) Min, Max 0.00, 4.00 Missing values 3 STIEFEL CONFIDENTIAL Page 38

40 Stiefel, a GSK company MaxClarity Clinical Study Report U Patient Preference Data Table Number Table 9.1 Table 9.2 Table 9.3 Table 9.4 Table 9.5 Table Title Subject s Preference Post-Study Questionnaire - Features Subject s Preference Post-Study Questionnaire Product - Statements Subject s Preference Post-Study Questionnaire - Acne Products Used in Past Subject s Preference Post-Study Questionnaire - Rating of Qualities of Foam Subject s Preference Post-Study Questionnaire - Foam Rating STIEFEL CONFIDENTIAL Page 39

41 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 9.1: Subject s Preference Post-Study Questionnaire Features ITT Analysis Set MaxClarity (n = 125) Less Embarrassed, n (%) 1 - Strongly disagree 5 (4.1%) 2 - Disagree 5 (4.1%) 3 - Neutral 45 (36.9%) 4 - Agree 54 (44.3%) 5 - Strongly agree 13 (10.7%) Missing 3 Mean ± SD 3.53 ± 0.89 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 Less Self-Conscious, n (%) 1 - Strongly disagree 6 (4.9%) 2 - Disagree 10 (8.2%) 3 - Neutral 30 (24.6%) 4 - Agree 67 (54.9%) 5 - Strongly agree 9 (7.4%) Missing 3 Mean ± SD 3.52 ± 0.93 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 More at Ease, n (%) 1 - Strongly disagree 3 (2.5%) 2 - Disagree 7 (5.7%) 3 - Neutral 39 (32.0%) 4 - Agree 58 (47.5%) 5 - Strongly agree 15 (12.3%) Missing 3 Mean ± SD 3.61 ± 0.87 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 Happier, n (%) 1 - Strongly disagree 3 (2.5%) 2 - Disagree 6 (4.9%) 3 - Neutral 40 (32.8%) 4 - Agree 56 (45.9%) 5 - Strongly agree 17 (13.9%) Missing 3 Mean ± SD 3.64 ± 0.87 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 Output: U Table 9.rtf Program: U Table 9.sas Source: Dataset QS_POST STIEFEL CONFIDENTIAL Page 40

42 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 9.1: Subject s Preference Post-Study Questionnaire (Continued) Features ITT Analysis Set MaxClarity (n = 125) More Self-Confident, n (%) 1 - Strongly disagree 4 (3.3%) 2 - Disagree 8 (6.6%) 3 - Neutral 41 (33.6%) 4 - Agree 49 (40.2%) 5 - Strongly agree 20 (16.4%) Missing 3 Mean ± SD 3.60 ± 0.95 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 More like myself, n (%) 1 - Strongly disagree 1 (0.8%) 2 - Disagree 10 (8.2%) 3 - Neutral 47 (38.5%) 4 - Agree 45 (36.9%) 5 - Strongly agree 19 (15.6%) Missing 3 Mean ± SD 3.58 ± 0.88 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 Less Frustrated, n (%) 1 - Strongly disagree 6 (4.9%) 2 - Disagree 16 (13.1%) 3 - Neutral 41 (33.6%) 4 - Agree 42 (34.4%) 5 - Strongly agree 17 (13.9%) Missing 3 Mean ± SD 3.39 ± 1.04 Median (P25, P75) 3.00 (3.00, 4.00) Min, Max 1.00, 5.00 More Attractive, n (%) 1 - Strongly disagree 3 (2.5%) 2 - Disagree 12 (9.8%) 3 - Neutral 43 (35.2%) 4 - Agree 49 (40.2%) 5 - Strongly agree 15 (12.3%) Missing 3 Mean ± SD 3.50 ± 0.92 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 Output: U Table 9.rtf Program: U Table 9.sas Source: Dataset QS_POST STIEFEL CONFIDENTIAL Page 41

43 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 9.1: Subject s Preference Post-Study Questionnaire (Continued) Features ITT Analysis Set Output: U Table 9.rtf Program: U Table 9.sas Source: Dataset QS_POST MaxClarity (n = 125) More Hopeful, n (%) 1 - Strongly disagree 1 (0.8%) 2 - Disagree 7 (5.7%) 3 - Neutral 38 (31.1%) 4 - Agree 58 (47.5%) 5 - Strongly agree 18 (14.8%) Missing 3 Mean ± SD 3.70 ± 0.82 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 Less Upset, n (%) 1 - Strongly disagree 3 (2.5%) 2 - Disagree 7 (5.7%) 3 - Neutral 53 (43.4%) 4 - Agree 40 (32.8%) 5 - Strongly agree 19 (15.6%) Missing 3 Mean ± SD 3.53 ± 0.91 Median (P25, P75) 3.00 (3.00, 4.00) Min, Max 1.00, 5.00 STIEFEL CONFIDENTIAL Page 42

44 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 9.rtf Program: U Table 9.sas Source: Dataset QS_POST Table 9.2: Subject s Preference Post-Study Questionnaire Product Statements ITT Analysis Set MaxClarity (n = 125) Continue to Use Study Products 1 - Strongly disagree 17 (13.9%) 2 - Disagree 11 (9.0%) 3 - Neutral 25 (20.5%) 4 - Agree 42 (34.4%) 5 - Strongly agree 27 (22.1%) Missing 3 Mean ± SD 3.42 ± 1.31 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 Satisfied with Study Products 1 - Strongly disagree 11 (9.0%) 2 - Disagree 8 (6.6%) 3 - Neutral 17 (13.9%) 4 - Agree 58 (47.5%) 5 - Strongly agree 28 (23.0%) Missing 3 Mean ± SD 3.69 ± 1.16 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 Easy to use with Make-Up 1 - Strongly disagree 2 (1.6%) 2 - Disagree 2 (1.6%) 3 - Neutral 3 (2.5%) 4 - Agree 30 (24.6%) 5 - Strongly agree 19 (15.6%) Not applicable, I don't wear makeup 66 (54.1%) Missing 3 Mean ± SD 4.11 ± 0.93 Median (P25, P75) 4.00 (4.00, 5.00) Min, Max 1.00, 5.00 STIEFEL CONFIDENTIAL Page 43

45 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 9.rtf Program: U Table 9.sas Source: Dataset QS_POST Table 9.3: Subject s Preference Post-Study Questionnaire Acne Products Used in Past ITT Analysis Set MaxClarity (n = 125) MaxClarity System Preference 1 - Liked the best 81 (66.9%) 2 - Liked second best 15 (12.4%) 3 - Liked third best 3 (2.5%) 4 - Liked fourth best 1 (0.8%) 5 - Liked the least 4 (3.3%) Does not apply to me 17 (14.0%) Missing 4 Mean ± SD 1.38 ± 0.91 Median (P25, P75) 1.00 (1.00, 1.00) Min, Max 1.00, 5.00 Proactiv System Preference 1 - Liked the best 10 (8.2%) 2 - Liked second best 31 (25.4%) 3 - Liked third best 5 (4.1%) 4 - Liked fourth best 2 (1.6%) 5 - Liked the least 5 (4.1%) Does not apply to me 69 (56.6%) Missing 3 Mean ± SD 2.26 ± 1.11 Median (P25, P75) 2.00 (2.00, 2.00) Min, Max 1.00, 5.00 Murad System Preference 1 - Liked the best 2 (1.6%) 2 - Liked second best 3 (2.5%) 3 - Liked third best 4 (3.3%) 4 - Liked fourth best 1 (0.8%) Does not apply to me 112 (91.8%) Missing 3 Mean ± SD 2.40 ± 0.97 Median (P25, P75) 2.50 (2.00, 3.00) Min, Max 1.00, 4.00 STIEFEL CONFIDENTIAL Page 44

46 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 9.3: Subject s Preference Post-Study Questionnaire (Continued) Acne Products Used in Past ITT Analysis Set Output: U Table 9.rtf Program: U Table 9.sas Source: Dataset QS_POST MaxClarity (n = 125) SkiniD System Preference 2 - Liked second best 1 (0.8%) 3 - Liked third best 2 (1.6%) 4 - Liked fourth best 1 (0.8%) 5 - Liked the least 1 (0.8%) Does not apply to me 117 (95.9%) Missing 3 Mean ± SD 3.40 ± 1.14 Median (P25, P75) 3.00 (3.00, 4.00) Min, Max 2.00, 5.00 Other Preference (specify) 1 - Liked the best 7 (8.5%) 2 - Liked second best 9 (11.0%) 3 - Liked third best 1 (1.2%) 5 - Liked the least 2 (2.4%) Does not apply to me 63 (76.8%) Missing 43 Mean ± SD 2.00 ± 1.20 Median (P25, P75) 2.00 (1.00, 2.00) Min, Max 1.00, 5.00 STIEFEL CONFIDENTIAL Page 45

47 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 9.rtf Program: U Table 9.sas Source: Dataset QS_POST Table 9.4: Subject s Preference Post-Study Questionnaire Rating of Qualities of Foam ITT Analysis Set MaxClarity (n = 125) Easy to Use 1 - Much Worse 1 (0.8%) 2 - Worse 8 (6.6%) 3 - About the same 27 (22.1%) 4 - Better 36 (29.5%) 5 - Much Better 39 (32.0%) Does not apply to me 11 (9.0%) Missing 3 Mean ± SD 3.94 ± 0.98 Median (P25, P75) 4.00 (3.00, 5.00) Min, Max 1.00, 5.00 Able to continue daily activities 1 - Much Worse 2 (1.6%) 2 - Worse 3 (2.5%) 3 - About the same 31 (25.4%) 4 - Better 32 (26.2%) 5 - Much Better 43 (35.2%) Does not apply to me 11 (9.0%) Missing 3 Mean ± SD 4.00 ± 0.97 Median (P25, P75) 4.00 (3.00, 5.00) Min, Max 1.00, 5.00 Leaves skin feeling soft 1 - Much Worse 2 (1.6%) 2 - Worse 13 (10.7%) 3 - About the same 33 (27.0%) 4 - Better 37 (30.3%) 5 - Much Better 26 (21.3%) Does not apply to me 11 (9.0%) Missing 3 Mean ± SD 3.65 ± 1.02 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 STIEFEL CONFIDENTIAL Page 46

48 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 9.4: Subject s Preference Post-Study Questionnaire (Continued) Rating of Qualities of Foam ITT Analysis Set Output: U Table 9.rtf Program: U Table 9.sas Source: Dataset QS_POST MaxClarity (n = 125) Disappears into skin quickly 1 - Much Worse 6 (4.9%) 2 - Worse 5 (4.1%) 3 - About the same 20 (16.4%) 4 - Better 39 (32.0%) 5 - Much Better 41 (33.6%) Does not apply to me 11 (9.0%) Missing 3 Mean ± SD 3.94 ± 1.11 Median (P25, P75) 4.00 (3.00, 5.00) Min, Max 1.00, 5.00 STIEFEL CONFIDENTIAL Page 47

49 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 9.rtf Program: U Table 9.sas Source: Dataset QS_POST Table 9.5: Subject s Preference Post-Study Questionnaire Foam Rating ITT Analysis Set MaxClarity (n = 125) Moisturizing 1-Very Poor 2 (1.6%) 2-Poor 13 (10.7%) 3-Fair 35 (28.7%) 4-Good 55 (45.1%) 5-Excellent 17 (13.9%) Missing 3 Mean ± SD 3.59 ± 0.92 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 Lack of residue 1-Very Poor 2 (1.6%) 2-Poor 15 (12.3%) 3-Fair 42 (34.4%) 4-Good 39 (32.0%) 5-Excellent 24 (19.7%) Missing 3 Mean ± SD 3.56 ± 1.00 Median (P25, P75) 4.00 (3.00, 4.00) Min, Max 1.00, 5.00 Does not feel greasy 2-Poor 8 (6.6%) 3-Fair 29 (23.8%) 4-Good 43 (35.2%) 5-Excellent 42 (34.4%) Missing 3 Mean ± SD 3.98 ± 0.92 Median (P25, P75) 4.00 (3.00, 5.00) Min, Max 2.00, 5.00 Absorbs quickly 1-Very Poor 1 (0.8%) 2-Poor 6 (4.9%) 3-Fair 25 (20.5%) 4-Good 52 (42.6%) 5-Excellent 38 (31.1%) Missing 3 Mean ± SD 3.98 ± 0.89 Median (P25, P75) 4.00 (3.00, 5.00) Min, Max 1.00, 5.00 STIEFEL CONFIDENTIAL Page 48

50 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 9.5: Subject s Preference Post-Study Questionnaire (Continued) Foam Rating ITT Analysis Set Output: U Table 9.rtf Program: U Table 9.sas Source: Dataset QS_POST MaxClarity (n = 125) Easy to apply 2-Poor 1 (0.8%) 3-Fair 16 (13.1%) 4-Good 49 (40.2%) 5-Excellent 56 (45.9%) Missing 3 Mean ± SD 4.31 ± 0.73 Median (P25, P75) 4.00 (4.00, 5.00) Min, Max 2.00, 5.00 Fragrance free 2-Poor 5 (4.1%) 3-Fair 19 (15.6%) 4-Good 55 (45.1%) 5-Excellent 43 (35.2%) Missing 3 Mean ± SD 4.11 ± 0.82 Median (P25, P75) 4.00 (4.00, 5.00) Min, Max 2.00, 5.00 Spreadability 2-Poor 1 (0.8%) 3-Fair 15 (12.3%) 4-Good 52 (42.6%) 5-Excellent 54 (44.3%) Missing 3 Mean ± SD 4.30 ± 0.71 Median (P25, P75) 4.00 (4.00, 5.00) Min, Max 2.00, 5.00 Lack of stickiness 1-Very Poor 3 (2.5%) 2-Poor 9 (7.4%) 3-Fair 22 (18.0%) 4-Good 39 (32.0%) 5-Excellent 49 (40.2%) Missing 3 Mean ± SD 4.00 ± 1.05 Median (P25, P75) 4.00 (3.00, 5.00) Min, Max 1.00, 5.00 STIEFEL CONFIDENTIAL Page 49

51 Stiefel, a GSK company MaxClarity Clinical Study Report U Safety Data Table Number Table 10.1 Table 10.2 Table 10.3 Table 10.4 Table 10.5 Table 10.6 Table 11 Table Title Incidence of Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set Incidence of Treatment-Emergent Adverse Events Classified by Preferred Term in Descending Order of Frequency ITT Analysis Set Incidence of Treatment-Related Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set Incidence of Severe Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set Incidence of Treatment-Emergent Adverse Events Resulting in Discontinuation Classified by System Organ Class and Preferred Term ITT Analysis Set Incidence of Serious Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set Prevalence of Concomitant Medication Use Classified by 2nd ATC level and Preferred Term ITT Analysis Set STIEFEL CONFIDENTIAL Page 50

52 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.1: Incidence of Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set MaxClarity (n = 125) SYSTEM ORGAN CLASS Preferred Term N (%) SUBJECTS REPORTING ANY ADVERSE EVENT 12 (9.6%) GASTROINTESTINAL DISORDERS 1 (0.8%) GASTROOESOPHAGEAL REFLUX DISEASE 1 (0.8%) IMMUNE SYSTEM DISORDERS 1 (0.8%) SEASONAL ALLERGY 1 (0.8%) INFECTIONS AND INFESTATIONS 7 (5.6%) NASOPHARYNGITIS 3 (2.4%) ORAL HERPES 2 (1.6%) PHARYNGITIS STREPTOCOCCAL 1 (0.8%) POST PROCEDURAL INFECTION 1 (0.8%) SINUSITIS 1 (0.8%) UPPER RESPIRATORY TRACT INFECTION 1 (0.8%) VULVOVAGINAL MYCOTIC INFECTION 1 (0.8%) INJURY, POISONING AND PROCEDURAL COMPLICATIONS 1 (0.8%) CONTUSION 1 (0.8%) NERVOUS SYSTEM DISORDERS 1 (0.8%) BURNING SENSATION 1 (0.8%) REPRODUCTIVE SYSTEM AND BREAST DISORDERS 1 (0.8%) OVARIAN CYST 1 (0.8%) RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS 1 (0.8%) RHINITIS ALLERGIC 1 (0.8%) SKIN AND SUBCUTANEOUS TISSUE DISORDERS 1 (0.8%) RASH 1 (0.8%) Subjects reporting a particular adverse event more than once are counted only once for that adverse event Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 51

53 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.2: Incidence of Treatment-Emergent Adverse Events Classified by Preferred Term in Descending Order of Frequency ITT Analysis Set MaxClarity (n = 125) PREFERRED TERM N (%) SUBJECTS REPORTING ANY ADVERSE EVENT 12 (9.6%) NASOPHARYNGITIS 3 (2.4%) ORAL HERPES 2 (1.6%) BURNING SENSATION 1 (0.8%) CONTUSION 1 (0.8%) GASTROOESOPHAGEAL REFLUX DISEASE 1 (0.8%) OVARIAN CYST 1 (0.8%) PHARYNGITIS STREPTOCOCCAL 1 (0.8%) POST PROCEDURAL INFECTION 1 (0.8%) RASH 1 (0.8%) RHINITIS ALLERGIC 1 (0.8%) SEASONAL ALLERGY 1 (0.8%) SINUSITIS 1 (0.8%) UPPER RESPIRATORY TRACT INFECTION 1 (0.8%) VULVOVAGINAL MYCOTIC INFECTION 1 (0.8%) Subjects reporting a particular adverse event more than once are counted only once for that adverse event Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 52

54 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.3: Incidence of Treatment-Related Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set No Treatment-Related Adverse Event was reported during this Study. Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 53

55 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.4: Incidence of Severe Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set MaxClarity (n = 125) SYSTEM ORGAN CLASS Preferred Term N (%) SUBJECTS REPORTING ANY ADVERSE EVENT 1 (0.8%) INFECTIONS AND INFESTATIONS 1 (0.8%) UPPER RESPIRATORY TRACT INFECTION 1 (0.8%) Subjects reporting a particular adverse event more than once are counted only once for that adverse event Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 54

56 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.5: Incidence of Treatment-Emergent Adverse Events Resulting in Discontinuation Classified by System Organ Class and Preferred Term ITT Analysis Set MaxClarity (n = 125) SYSTEM ORGAN CLASS Preferred Term N (%) SUBJECTS REPORTING ANY ADVERSE EVENT 1 (0.8%) SKIN AND SUBCUTANEOUS TISSUE DISORDERS 1 (0.8%) RASH 1 (0.8%) Subjects reporting a particular adverse event more than once are counted only once for that adverse event Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 55

57 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.6: Incidence of Serious Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set No Serious Adverse Event was reported during this Study. Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 56

58 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 11: Prevalence of Concomitant Medication Use Classified by 2nd ATC Level and Preferred Term ITT Analysis Set MaxClarity (n = 125) DRUG CLASSIFICATION N (%) Medication ADRENERGICS AND OTH.DRUGS FOR OBSTRUCT.AIRWAY DIS. 1 (0.8%) Seretide 1 (0.8%) AMINOALKYL ETHERS 5 (4.0%) Diphenhydramine 5 (4.0%) ANILIDES 5 (4.0%) Benadryl cold and flu 1 (0.8%) Pamprin 1 (0.8%) Paracetamol 2 (1.6%) Thomapyrin n 1 (0.8%) ANTIALLERGIC AGENTS, EXCL. CORTICOSTEROIDS 1 (0.8%) Olopatadine 1 (0.8%) ANTIINFECTIVES FOR TREATMENT OF ACNE 2 (1.6%) Clindamycin 1 (0.8%) Doxycycline 1 (0.8%) ANTIVIRALS 1 (0.8%) Aciclovir 1 (0.8%) BETA BLOCKING AGENTS, SELECTIVE 2 (1.6%) Metoprolol 2 (1.6%) CALCIUM 1 (0.8%) Calcium carbonate 1 (0.8%) CARBAMIDE PRODUCTS 1 (0.8%) Urea 1 (0.8%) CENTRALLY ACTING SYMPATHOMIMETICS 6 (4.8%) Lisdexamfetamine 1 (0.8%) Methylphenidate 3 (2.4%) Obetrol 2 (1.6%) COMB OF PENICILLINS, INCL. BETA-LACTAMASE INHIB. 1 (0.8%) Augmentin 1 (0.8%) COMB.SULFONAMIDES & TRIMETHOPRIM INCL. DERIVATIVES 1 (0.8%) Bactrim 1 (0.8%) CORTICOSTEROIDS 2 (1.6%) Fluticasone 2 (1.6%) CORTICOSTEROIDS, POTENT (GROUP III) 2 (1.6%) Betamethasone 1 (0.8%) Fluocinonide 1 (0.8%) Subjects reporting a particular concomitant medication more than once are counted only once for that drug Output: U Table 11.rtf Program: U Table 11.sas Source: Dataset CM STIEFEL CONFIDENTIAL Page 57

59 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 11: Prevalence of Concomitant Medication Use (Continued) Classified by 2nd ATC Level and Preferred Term ITT Analysis Set MaxClarity (n = 125) CORTICOSTEROIDS, VERY POTENT (GROUP IV) 1 (0.8%) Clobetasol 1 (0.8%) DIPHENYLMETHANE DERIVATIVES 1 (0.8%) Hydroxyzine 1 (0.8%) EXPECTORANTS 1 (0.8%) Guaifenesin 1 (0.8%) GLUCOCORTICOIDS 1 (0.8%) Fluticasone 1 (0.8%) H2-RECEPTOR ANTAGONISTS 1 (0.8%) Famotidine 1 (0.8%) IMIDAZOLE AND TRIAZOLE DERIVATIVES 1 (0.8%) Ketoconazole 1 (0.8%) IMIDAZOLE DERIVATIVES 1 (0.8%) Miconazole 1 (0.8%) INSULINS AND ANALOGUES 1 (0.8%) Insulin 1 (0.8%) INTRAUTERINE CONTRACEPTIVES 2 (1.6%) Intrauterine contraceptive device 2 (1.6%) INTRAVAGINAL CONTRACEPTIVES 11 (8.8%) Intravaginal contraceptives 11 (8.8%) MACROLIDES 1 (0.8%) Azithromycin 1 (0.8%) MULTIVITAMINS WITH MINERALS 2 (1.6%) Multivitamins plus iron 1 (0.8%) Prenatal vitamins 1 (0.8%) MULTIVITAMINS, PLAIN 10 (8.0%) Multivitamin 10 (8.0%) NATURAL OPIUM ALKALOIDS 1 (0.8%) Panadeine co 1 (0.8%) OTHER ANTIDEPRESSANTS 3 (2.4%) Bupropion 1 (0.8%) Trazodone 2 (1.6%) OTHER ANTIEPILEPTICS 1 (0.8%) Lamotrigine 1 (0.8%) Zonisamide 1 (0.8%) OTHER ANTIFUNGALS FOR TOPICAL USE 1 (0.8%) Naftifine 1 (0.8%) Subjects reporting a particular concomitant medication more than once are counted only once for that drug Output: U Table 11.rtf Program: U Table 11.sas Source: Dataset CM STIEFEL CONFIDENTIAL Page 58

60 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 11: Prevalence of Concomitant Medication Use (Continued) Classified by 2nd ATC Level and Preferred Term ITT Analysis Set MaxClarity (n = 125) OTHER ANTIHISTAMINES FOR SYSTEMIC USE 3 (2.4%) Fexofenadine 2 (1.6%) Loratadine 1 (0.8%) OTHER EMOLLIENTS AND PROTECTIVES 2 (1.6%) Dimeticone 1 (0.8%) Other emollients and protectives 1 (0.8%) OTHER LIPID MODIFYING AGENTS 1 (0.8%) Fish oil 1 (0.8%) OTHER NASAL PREPARATIONS 1 (0.8%) Sodium chloride 1 (0.8%) OTHER PLAIN VITAMIN PREPARATIONS 1 (0.8%) Biotin 1 (0.8%) OXICAMS 1 (0.8%) Meloxicam 1 (0.8%) PENICILLINS WITH EXTENDED SPECTRUM 1 (0.8%) Amoxicillin 1 (0.8%) PIPERAZINE DERIVATIVES 6 (4.8%) Cetirizine 6 (4.8%) PREPARATIONS CONTAINING SULFUR 1 (0.8%) Rosula 1 (0.8%) PROGESTOGENS AND ESTROGENS, FIXED COMBINATIONS 9 (7.2%) Anovlar 2 (1.6%) Cilest 4 (3.2%) Drospirenone w/ethinylestradiol 1 (0.8%) Eugynon 1 (0.8%) Norlestrin fe 1 (0.8%) PROPIONIC ACID DERIVATIVES 6 (4.8%) Ibuprofen 5 (4.0%) Naproxen 1 (0.8%) SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS 4 (3.2%) Salbutamol 4 (3.2%) SELECTIVE SEROTONIN REUPTAKE INHIBITORS 4 (3.2%) Citalopram 2 (1.6%) Fluoxetine 1 (0.8%) Paroxetine 1 (0.8%) SYMPATHOMIMETICS 1 (0.8%) Pseudoephedrine 1 (0.8%) UNSPECIFIED HERBAL 2 (1.6%) Herbal preparation 2 (1.6%) Subjects reporting a particular concomitant medication more than once are counted only once for that drug Output: U Table 11.rtf Program: U Table 11.sas Source: Dataset CM STIEFEL CONFIDENTIAL Page 59

61 Stiefel, a GSK company MaxClarity Clinical Study Report U Protocol and Protocol Amendments STIEFEL CONFIDENTIAL Page 60

62 Stiefel, a GSK company MaxClarity Clinical Study Report U AN OPEN LABEL, 12 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE MAXCLARITY SYSTEM (BENZOYL PEROXIDE 2.5%, SALICYLIC ACID 0.5%) IN SUBJECTS WITH ACNE CLINICAL STUDY REPORT U (4 WEEK INTERIM DATA) VERSION May 2012 Sponsored by: Stiefel, a GSK company 20 TW Alexander Drive Research Triangle Park North Carolina, Conducted by: Stiefel, a GSK company 20 TW Alexander Drive Research Triangle Park North Carolina, THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE LICENSING AND/OR REGISTRATION OF PRODUCTS FOR STIEFEL OR ITS AFFILIATED COMPANIES. THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN WHOLE OR IN PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF STIEFEL. STIEFEL CONFIDENTIAL Page 1

63 Stiefel, a GSK company MaxClarity Clinical Study Report U TITLE PAGE An Open Label, 12 Week Study to Evaluate the Efficacy and Safety of the MaxClarity System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne Name of Investigational Product Indication Description MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA). Acne Open Label, 12-week efficacy and safety evaluation of the MaxClarity System in facial acne. Stiefel, a GSK company Sponsor Protocol/Study Number U Development Phase Consumer Health Non-Prescription Post-Launch Study Study Initiation Date 23 June 2011 Study Completion Date Ongoing Sponsor s Responsible MD Medical Officer Consultant Stiefel, a GSK company Responsible Signatory MD Consultant Stiefel, a GSK company Date of the report 22 May 2012 This study was performed in accordance with Good Clinical Practices, including guidelines outlined by the International Conference on Harmonisation. STIEFEL CONFIDENTIAL Page 2

64 Stiefel, a GSK company MaxClarity Clinical Study Report U SYNOPSIS NAME OF SPONSOR/COMPANY: Stiefel, a GSK company NAME OF FINISHED PRODUCT: MaxClarity System: MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA) NAME OF ACTIVE INGREDIENT(S): 2.5% benzoyl peroxide, 0.5% salicylic acid INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Not applicable Page: Not applicable (FOR NATIONAL AUTHORITY USE ONLY) Title of study: An Open Label, 12 Week Study to Evaluate the Efficacy and Safety of the MaxClarity System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne. Investigators: MD MD MD MD MD MD MD MD MD Publication (reference): No publications related to this study were published as of the date of this report. Study initiation/completion dates: The first subject was enrolled on 23 June The study is ongoing and the last subject is pending. Phase of Development: n/a Objectives: The primary objective was to assess the efficacy of the MaxClarity System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%), which includes MaxClarity Foam Deep Cleanser (2.5% BPO) and MaxClarity Foam Advanced Acne Treatment (2.5% BPO) and MaxClarity Foam Rejuvenating Toner (0.5% SA), in the treatment of moderate to severe acne. The secondary objective was to evaluate the safety and subject satisfaction of this treatment regimen. Methodology: This was a multi-center, open label, safety and efficacy study. One-hundred twenty (120) male/female subjects, 12 to 35 years of age, were to be enrolled into this study. The study duration is 12 weeks (84 days) with study visits occurring at baseline (day 1), week 1, week 2, week 4, week 8, and week 12. Number of subjects (planned and analyzed): 120 subjects planned; 125 enrolled and applied study medication. Diagnosis and Main Criteria for Inclusion: - Capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed. - Male or female ages 12 to 35 years, inclusive, at time of consent. - Investigator s Static Global Assessment (ISGA) score of 3 or 4 at Baseline. - Lesion counts meeting all of the following criteria: A minimum of 25 but not more than 50 facial inflammatory lesions (papules and pustules), excluding nasal lesions. A minimum of 20 but not more than 100 facial noninflammatory lesions (open and closed comedones) on the face, excluding nasal lesions. No more than 3 facial nodular lesions (<5 mm), with no cystic lesions. STIEFEL CONFIDENTIAL Page 3

65 Stiefel, a GSK company MaxClarity Clinical Study Report U NAME OF SPONSOR/COMPANY: Stiefel, a GSK company NAME OF FINISHED PRODUCT: MaxClarity System: MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA) NAME OF ACTIVE INGREDIENT(S): 2.5% benzoyl peroxide, 0.5% salicylic acid INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Not applicable Page: Not applicable (FOR NATIONAL AUTHORITY USE ONLY) - Able and willing to follow all study procedures, attend all visits, and successfully complete the study. - Female subjects of childbearing potential (CBP) required a negative pregnancy test. Sexually active women of CBP participating in the study must have been using a medically acceptable method of contraception. Duration of Study: 12 weeks. Test Product, Dose and Mode of Administration, Batch No.: Max Clarity Foam Deep Cleanser (2.5% BPO; Lot D0J567). Max Clarity Foam Advanced Acne Treatment (2.5% BPO; Lot D0J589). Max Clarity Foam Rejuvenating Toner (0.5% SA; Lot D0J571). AM regimen (wash face with Foam Deep Cleanser, pat dry, apply thin layer of Foam Advanced Acne Treatment); PM regimen (wash face with Foam Deep Cleanser, pat dry, apply Foam Rejuvenating Toner). Criteria for Evaluation: Efficacy: Primary endpoints: - Mean percent change from baseline in inflammatory, non-inflammatory and total lesion counts at each study visit. - Proportion of subjects with a minimum 2-grade improvement in ISGA from Baseline to each study visit. - Proportion of subjects with an ISGA score of 0 (clear) or 1 (almost clear) at each study visit. Secondary endpoints: - Absolute change in inflammatory, non-inflammatory and total lesion counts from Baseline to each study visit. - Mean change in ISGA from Baseline to each study visit. - Post-Inflammatory Hyper pigmentation (Overall Severity) at each study visit. - Post-Inflammatory Hyper pigmentation (Distribution of PIH; % of face affected) at each study visit. - Subject Global Improvement Scale. Patient Preference: - Subject Preference Post-Study Questionnaire. Safety: - Adverse Event reporting. - Concomitant medication use. Statistical Methods: All statistical analyses were performed on the intent-to-treat (ITT) analysis set using SAS software (version 9.2). The ITT analysis set included data from all subjects that were enrolled into the study. A formal sample size calculation was not conducted. No formal statistical hypothesis was formulated for this study. Data are presented in a descriptive fashion and as reported in the case report form (CRF). No inferential statistical testing was conducted and no estimation of missing data was performed. No particular processing for outliers was performed. Descriptive statistics are used to provide an overview of the efficacy and tolerability and safety results. For categorical parameters, the number and percentage of subjects in each category are presented. The denominator for percentage is based on the number of subjects appropriate for the purpose of analysis. For continuous parameters, descriptive statistics include n (number of subjects), mean, standard deviation (STD), median, and range. No estimation of missing data was performed. Age is calculated in years (1 year = STIEFEL CONFIDENTIAL Page 4

66 Stiefel, a GSK company MaxClarity Clinical Study Report U NAME OF SPONSOR/COMPANY: Stiefel, a GSK company NAME OF FINISHED PRODUCT: MaxClarity System: MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA) NAME OF ACTIVE INGREDIENT(S): 2.5% benzoyl peroxide, 0.5% salicylic acid INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Not applicable Page: Not applicable (FOR NATIONAL AUTHORITY USE ONLY) days) from birth date to the first dose date and presented with one decimal. No particular processing for outliers was performed. Data is presented as reported in the CRF. For the final analysis, Adverse Events (AEs) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA, Version 14.1) by system organ class (SOC) and preferred term. Tables summarizing subject incidence of all AEs, serious AEs, severe AEs, treatment-related AEs, treatment-related serious AEs, and treatment-related severe AEs will be provided. All summaries will include treatment emergent events only. Also for the final analysis, prior and concomitant medications will be coded according to the World Health Organization Drug Dictionary (WHODrug) January Individual subject listings of all data represented on the CRF were produced, but are not included with this report. In general, one listing was produced per CRF domain which was sorted by subject number. Additional listings were prepared to support selected summary tables. Individual subject listings will be provided upon request. SUMMARY CONCLUSIONS Efficacy Results: Primary analyses: Lesion counts: At week 4, clinically significant reductions in all lesion types were seen. Mean ± SD percent reduction from baseline of ± 23.6% in total lesions was noted. Inflammatory lesions appeared more responsive than noninflammatory lesions to study product. At week 4, reductions from baseline in inflammatory and noninflammatory lesions were ± 27.0% and ± 30.1%, respectively. At week 1 and week 2, clinically significant reductions from baseline were noted with all lesion outcomes (see Table 1 below and section 5.2.2, Summary Tables 5.1, 5.2 and 5.3). Table 1. Summary of Primary Efficacy Results Lesion Counts Primary Efficacy Outcomes Mean percent change in inflammatory lesion count from baseline to: Mean percent change in noninflammatory lesion count from baseline to: Mean percent change in total lesion count from baseline to: Source: Summary Tables 5.1, 5.2, 5.3, section MaxClarity II (mean ± SD) week ± 25.8% week ± 26.4% week ± 27.0% week ± 24.4% week ± 24.4% week ± 30.1% week ± 20.6% week ± 21.5% week ± 23.6% The proportion of subjects achieving minimal 2-grade improvement in the ISGA at week 4 was 10.0% (12/120 subjects). At week 1 and week 2, 2.5% (3/120 subjects) and 5.0% (6/121 subjects) achieved this threshold, respectively. The proportion of subjects with an IGSA score of 0 (clear) or 1 (almost clear) at week 1, week 2 and week 4 was 0.8% (1/120 subjects), 1.7% (2/121 subjects) and 3.3% (4/120 subjects), respectively (see STIEFEL CONFIDENTIAL Page 5

67 Stiefel, a GSK company MaxClarity Clinical Study Report U NAME OF SPONSOR/COMPANY: Stiefel, a GSK company NAME OF FINISHED PRODUCT: MaxClarity System: MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA) NAME OF ACTIVE INGREDIENT(S): 2.5% benzoyl peroxide, 0.5% salicylic acid Table 1 below and section 5.2.2, Summary Table 6). INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Not applicable Page: Not applicable (FOR NATIONAL AUTHORITY USE ONLY) Table 2. Summary of Primary Efficacy Results ISGA Primary Efficacy Outcomes Proportion of subjects with a > 2-grade improvement from Baseline to: Proportion of subjects with a score of 0 (clear) or 1 (almost clear): Source: Summary Table 6, section MaxClarity II n (%) week 1 3 (2.5%) week 2 6 (5.0%) week 4 12 (10.0%) week 1 1 (0.8%) week 2 2 (1.7%) week 4 4 (3.3%) Secondary analyses: Absolute change in lesion counts: At week 1, week 2, and week 4, the mean ± SD change in inflammatory lesions from baseline was -9.6 ± 8.2, ± 8.9, and ± 9.3 lesions, respectively. The mean change in noninflammatory lesions from baseline was -7.4 ± 12.1, ± 13.5, and ± 15.4 lesions at week 1, week 2, and week 4, respectively. The mean change in total lesions from baseline was ± 16.6, ± 18.8, and ± 20.3 lesions at week 1, week 2, and week 4, respectively (see section 5.2.2, Summary Table 5.1, 5.2 and 5.3). Mean change in ISGA: The mean ± SD change in ISGA from baseline was ± 0.51, ± 0.61, and ± 0.69 at week 1, week 2, and week 4, respectively (see section 5.2.2, Summary Table 6). Mean change in Post-Inflammatory Hyperpigmentation: The mean ± SD change from baseline in PIH Overall Severity was ± 0.35, ± 0.58, and ± 0.51 at week 1, week 2, and week 4, respectively (see section 5.2.2, Summary Table 7.1). The mean change from baseline in PIH distribution was ± 0.27, ± 0.32, and ± 0.38 at week 1, week 2, and week 4, respectively (see section 5.2.2, Summary Table 7.2). Subject Global Improvement Scale: The mean ± SD change from baseline in Subject Global Improvement was 1.95 ± 0.82, 2.07 ± 0.82, and 2.28 ± 0.85 at week 1, week 2, and week 4, respectively (see section 5.2.2, Summary Table 8). Patient Preference Results: Subject s Preference Post-Study Questionnaire data will be presented in the final analysis. Safety Results: After 4 weeks of treatment, no treatment-related AE have been noted. One subject was withdrawn from study participation due to the occurrence of non-treatment related adverse events (rash on face). There were no SAEs. Conclusions: Clinically significant reductions in all acne lesion counts at weeks 1, 2 and 4 with the MaxClarity System. MaxClarity was also well tolerated with no treatment-related AEs or SAEs reported by week 4. STIEFEL CONFIDENTIAL Page 6

68 Stiefel, a GSK company MaxClarity Clinical Study Report U NAME OF SPONSOR/COMPANY: Stiefel, a GSK company NAME OF FINISHED PRODUCT: MaxClarity System: MaxClarity Foam Deep Cleanser (2.5% BPO), MaxClarity Foam Advanced Acne Treatment (2.5% BPO), and MaxClarity Foam Rejuvenating Toner (0.5% SA) NAME OF ACTIVE INGREDIENT(S): 2.5% benzoyl peroxide, 0.5% salicylic acid INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Not applicable Page: Not applicable (FOR NATIONAL AUTHORITY USE ONLY) Date of the report: 22 May 2012 Signatur Date: MD Consultant Stiefel, a GSK company STIEFEL CONFIDENTIAL Page 7

69 Stiefel, a GSK company MaxClarity Clinical Study Report U TABLE OF CONTENTS 1 TITLE PAGE SYNOPSIS TABLE OF CONTENTS REFERENCE LIST APPENDICES Safety Evaluation Extent of Exposure Adverse Events Brief Summary of Adverse Events Display of Adverse Events Analysis of Adverse Events Listing of Adverse Events by Subject Deaths, Other Serious Adverse Events, and Other Significant Adverse Events Listing of Deaths, Other SAEs, and Other Significant AEs Narratives of Deaths, Other SAEs, and Certain Other Significant AEs Analysis and Discussion of Deaths, Other SAEs, and Other Significant AEs Clinical Laboratory Evaluation Vital Signs, Physical Findings, and Other Observations Related to Safety Safety Conclusions Tables, Figures and Graphs Referred to but not Included in the Text Subject Disposition and Demographic Data Efficacy Data Quality of Life and Patient Preference Data Safety Data Protocol and Protocol Amendments STIEFEL CONFIDENTIAL Page 8

70 Stiefel, a GSK company MaxClarity Clinical Study Report U REFERENCE LIST No references cited. STIEFEL CONFIDENTIAL Page 9

71 Stiefel, a GSK company MaxClarity Clinical Study Report U APPENDICES 5.1 Safety Evaluation Extent of Exposure A total of 125 subjects consented and were enrolled in this study. For this interim analysis, the mean number of days exposed, the minimum exposure and the maximum exposure are not available Adverse Events (AEs) Brief Summary of Adverse Events A total of 11 subjects (8.8%) reported experiencing at least 1 treatment-emergent AE (see section 5.2.4, Summary Table 10.1). Of these, no subject experienced a treatment-related AE. No serious adverse events (SAE) were reported Display of Adverse Events The most common treatment-emergent AEs were related to the system organ class (SOC) of Infections and Infestations with 10 subjects (35.7%) experiencing such events (see Table 1 below and section 5.2.4, Summary Table 10.1). STIEFEL CONFIDENTIAL Page 10

72 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 1. Incidence of Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term (ITT Analysis Set) Total (n = 125) SYSTEM ORGAN CLASS N (%) Preferred Term SUBJECTS REPORTING ANY ADVERSE EVENT 11 (8.8%) GASTROINTESTINAL DISORDERS 1 (0.8%) Gastrooesophageal Reflux Disease 1 (0.8%) IMMUNE SYSTEM DISORDERS 1 (0.8%) Seasonal Allergy 1 (0.8%) INFECTIONS AND INFESTATIONS 6 (4.8%) Nasopharyngitis 3 (2.4%) Oral Herpes 2 (1.6%) Pharyngitis Streptococcal 1 (0.8%) Sinusitis 1 (0.8%) Upper Respiratory Tract Infection 1 (0.8%) Vulvovaginal Mycotic Infection 1 (0.8%) INJURY, POISONING AND PROCEDURAL COMPLICATIONS 1 (0.8%) Contusion 1 (0.8%) NERVOUS SYSTEM DISORDERS 1 (0.8%) Burning Sensation 1 (0.8%) REPRODUCTIVE SYSTEM AND BREAST DISORDERS 1 (0.8%) Ovarian Cyst 1 (0.8%) RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS 1 (0.8%) Rhinitis Allergic 1 (0.8%) SKIN AND SUBCUTANEOUS TISSUE DISORDERS 1 (0.8%) Rash 1 (0.8%) Subjects reporting a particular adverse event more than once are counted only once for that adverse event Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE Analysis of Adverse Events Study products were safe and well tolerated with no treatment-related AE being noted Listing of Adverse Events by Subject Listings will be provided upon request Deaths, Other Serious Adverse Events, and Other Significant Adverse Events Listing of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events No deaths, serious adverse events, or other significant adverse events have yet been reported. STIEFEL CONFIDENTIAL Page 11

73 Stiefel, a GSK company MaxClarity Clinical Study Report U Narratives of Deaths, Other Serious Adverse Events, and Certain Other Significant Adverse Events No deaths, serious adverse events, or other significant adverse events have yet been reported Analysis and Discussion of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events No deaths, serious adverse events, or other significant adverse events have yet been reported Clinical Laboratory Evaluation Clinical laboratory evaluations were not included as part of study procedures, but may be recorded in support of adverse event diagnosis or follow up Vital Signs, Physical Findings, and Other Observations Related to Safety Vital signs and physical examinations were not recorded as part of study procedures, but may be recorded in support of adverse event diagnosis or follow up Safety Conclusions MaxClarity was well tolerated with no treatment-related AEs or SAEs reported by week 4. STIEFEL CONFIDENTIAL Page 12

74 Stiefel, a GSK company MaxClarity Clinical Study Report U Tables, Figures and Graphs Referred to but not Included in the Text Subject Disposition and Demographic Data Table Number Table 1 Table 2 Table 3 Table 4 Table Title Subject Disposition - ITT Analysis Set Demographics - ITT Analysis Set Baseline Disease Characteristics - ITT Analysis Set Treatment Duration ITT Analysis Set STIEFEL CONFIDENTIAL Page 13

75 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 1: Subject Disposition ITT Analysis Set This table will be produced for the final statistical analysis. STIEFEL CONFIDENTIAL Page 14

76 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 2.rtf Program: U Table 2.sas Source: Dataset DM Table 2: Demographics ITT Analysis Set Total (n = 125) Age (years) N 125 Mean ± SD 19.0 ± 5.7 Median (P25, P75) 16.9 (15.1, 20.8) Min, Max 12.1, 35.7 Sex, n (%) Male 57 (45.6%) Female 68 (54.4%) Race, n (%) American Indian or Alaskan Native 7 (5.6%) Asian 9 (7.2%) Black 21 (16.8%) Native Hawaiian or Other Pacific Islander 1 (0.8%) White 84 (67.2%) Other 3 (2.4%) Ethnicity, n (%) Hispanic or Latino 27 (21.6%) Not Hispanic or Latino 98 (78.4%) STIEFEL CONFIDENTIAL Page 15

77 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 3.rtf Program: U Table 3.sas Source: Dataset EF_BSL Table 3: Baseline Disease Characteristics ITT Analysis Set Total (n = 125) Investigator Static Global Assessment, n (%) 3- Moderate 84 (67.2%) 4- Severe 41 (32.8%) Inflammatory Lesion Count N 125 Mean ± SD 32.2 ± 6.7 Median (P25, P75) 29.0 (27.0, 37.0) Min, Max 25.0, 50.0 Non-Inflammatory Lesion Count N 125 Mean ± SD 46.5 ± 21.0 Median (P25, P75) 41.0 (28.0, 58.0) Min, Max 21.0, 97.0 Total Lesion Count N 125 Mean ± SD 78.7 ± 24.5 Median (P25, P75) 75.0 (57.0, 92.0) Min, Max 47.0, Post-Inflammatory Hyperpigmentation Severity, n (%) 0- Absent 51 (40.8%) 1- Slight 15 (12.0%) 2- Mild 41 (32.8%) 3- Moderate 17 (13.6%) 4- Moderately Severe 1 (0.8%) Post-Inflammatory Hyperpigmentation Distribution, n (%) 0- None 54 (43.2%) % of the face 27 (21.6%) % of the face 32 (25.6%) % of the face 11 (8.8%) % of the face 1 (0.8%) STIEFEL CONFIDENTIAL Page 16

78 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 4: Study Product Exposure ITT Analysis Set This table will be produced for the final statistical analysis. STIEFEL CONFIDENTIAL Page 17

79 Stiefel, a GSK company MaxClarity Clinical Study Report U Efficacy Data Table Number Table 5.1 Table 5.2 Table 5.3 Table 6 Table 7.1 Table 7.2 Table 8 Table Title Lesion Counts Inflammatory Lesions ITT Analysis Set Lesion Counts Non-Inflammatory Lesions ITT Analysis Set Lesion Counts Total Lesions ITT Analysis Set Investigator Static Global Assessment ITT Analysis Set Post-Inflammatory Hyperpigmentation Assessments Severity ITT Analysis Set Post-Inflammatory Hyperpigmentation Assessments Distribution ITT Analysis Set Subject s Global Improvement Scale ITT Analysis Set STIEFEL CONFIDENTIAL Page 18

80 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.1: Lesion Counts Inflammatory Lesions ITT Analysis Set Total (n = 125) Baseline (Day 1) N 125 Mean ± SD 32.2 ± 6.7 Median (P25, P75) 29.0 (27.0, 37.0) Min, Max 25.0, 50.0 Week 1 N 120 Mean ± SD 22.6 ± 10.0 Median (P25, P75) 22.0 (17.0, 28.5) Min, Max 0.0, 50.0 Missing values 5 Change from Baseline to Week 1 N 120 Mean ± SD -9.6 ± 8.2 Median (P25, P75) -8.0 (-14.5, -3.0) Min, Max -35.0, 9.0 Missing values 5 % Change from Baseline to Week 1 N 120 Mean ± SD ± 25.8 Median (P25, P75) (-48.1, -11.4) Min, Max , 25.7 Missing values 5 Week 2 N 121 Mean ± SD 18.0 ± 10.0 Median (P25, P75) 17.0 (11.0, 23.0) Min, Max 2.0, 52.0 Missing values 4 Change from Baseline to Week 2 N 121 Mean ± SD ± 8.9 Median (P25, P75) (-20.0, -8.0) Min, Max -41.0, 12.0 Missing values 4 STIEFEL CONFIDENTIAL Page 19

81 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.1: Lesion Counts (Continued) Inflammatory Lesions ITT Analysis Set Total (n = 125) % Change from Baseline to Week 2 N 121 Mean ± SD ± 26.4 Median (P25, P75) (-64.4, -25.9) Min, Max -93.1, 30.0 Missing values 4 Week 4 N 120 Mean ± SD 15.3 ± 9.8 Median (P25, P75) 14.0 (8.0, 20.0) Min, Max 0.0, 53.0 Missing values 5 Change from Baseline to Week 4 N 120 Mean ± SD ± 9.3 Median (P25, P75) (-23.5, -10.0) Min, Max -47.0, 4.0 Missing values 5 % Change from Baseline to Week 4 N 120 Mean ± SD ± 27.0 Median (P25, P75) (-74.5, -34.3) Min, Max , 11.4 Missing values 5 STIEFEL CONFIDENTIAL Page 20

82 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.2: Lesion Counts Non-Inflammatory Lesions ITT Analysis Set Total (n = 125) Baseline (Day 1) N 125 Mean ± SD 46.5 ± 21.0 Median (P25, P75) 41.0 (28.0, 58.0) Min, Max 21.0, 97.0 Week 1 N 120 Mean ± SD 39.0 ± 20.2 Median (P25, P75) 32.0 (25.0, 50.0) Min, Max 13.0, 96.0 Missing values 5 Change from Baseline to Week 1 N 120 Mean ± SD -7.4 ± 12.1 Median (P25, P75) -6.0 (-13.0, 0.0) Min, Max -43.0, 25.0 Missing values 5 % Change from Baseline to Week 1 N 120 Mean ± SD ± 24.4 Median (P25, P75) (-31.0, 0.0) Min, Max -70.9, 78.6 Missing values 5 Week 2 N 121 Mean ± SD 33.0 ± 19.6 Median (P25, P75) 26.0 (20.0, 41.0) Min, Max 5.0, 94.0 Missing values 4 Change from Baseline to Week 2 N 121 Mean ± SD ± 13.5 Median (P25, P75) (-21.0, -5.0) Min, Max -63.0, 18.0 Missing values 4 STIEFEL CONFIDENTIAL Page 21

83 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.2: Lesion Counts (Continued) Non-Inflammatory Lesions ITT Analysis Set Total (n = 125) % Change from Baseline to Week 2 N 121 Mean ± SD ± 24.4 Median (P25, P75) (-44.2, -14.6) Min, Max -89.3, 31.8 Missing values 4 Week 4 N 120 Mean ± SD 29.2 ± 18.7 Median (P25, P75) 24.5 (15.0, 38.0) Min, Max 5.0, 95.0 Missing values 5 Change from Baseline to Week 4 N 120 Mean ± SD ± 15.4 Median (P25, P75) (-27.5, -8.5) Min, Max -57.0, 21.0 Missing values 5 % Change from Baseline to Week 4 N 120 Mean ± SD ± 30.1 Median (P25, P75) (-58.4, -21.5) Min, Max -87.8, 51.2 Missing values 5 STIEFEL CONFIDENTIAL Page 22

84 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.3: Lesion Counts Total Lesions ITT Analysis Set Total (n = 125) Baseline (Day 1) N 125 Mean ± SD 78.7 ± 24.5 Median (P25, P75) 75.0 (57.0, 92.0) Min, Max 47.0, Week 1 N 120 Mean ± SD 61.6 ± 26.8 Median (P25, P75) 54.0 (43.0, 76.0) Min, Max 16.0, Missing values 5 Change from Baseline to Week 1 N 120 Mean ± SD ± 16.6 Median (P25, P75) (-28.0, -5.0) Min, Max -59.0, 25.0 Missing values 5 % Change from Baseline to Week 1 N 120 Mean ± SD ± 20.6 Median (P25, P75) (-35.9, -7.4) Min, Max -73.8, 28.7 Missing values 5 Week 2 N 121 Mean ± SD 50.9 ± 26.1 Median (P25, P75) 45.0 (32.0, 66.0) Min, Max 7.0, Missing values 4 Change from Baseline to Week 2 N 121 Mean ± SD ± 18.8 Median (P25, P75) (-40.0, -15.0) Min, Max , 8.0 Missing values 4 STIEFEL CONFIDENTIAL Page 23

85 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 5.rtf Program: U Table 5.sas Source: Datasets EF_BSL & EF_VISITS Table 5.3: Lesion Counts (Continued) Total Lesions ITT Analysis Set Total (n = 125) % Change from Baseline to Week 2 N 121 Mean ± SD ± 21.5 Median (P25, P75) (-51.5, -21.4) Min, Max -88.4, 9.3 Missing values 4 Week 4 N 120 Mean ± SD 44.4 ± 25.1 Median (P25, P75) 40.0 (25.5, 57.5) Min, Max 8.0, Missing values 5 Change from Baseline to Week 4 N 120 Mean ± SD ± 20.3 Median (P25, P75) (-49.0, -22.5) Min, Max -87.0, 22.0 Missing values 5 % Change from Baseline to Week 4 N 120 Mean ± SD ± 23.6 Median (P25, P75) (-62.4, -28.5) Min, Max -91.6, 25.6 Missing values 5 STIEFEL CONFIDENTIAL Page 24

86 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 6.rtf Program: U Table 6.sas Source: Datasets EF_BSL & EF_VISITS Table 6: Investigator Static Global Assessment ITT Analysis Set Total (n = 125) Baseline (Day 1), n (%) 3- Moderate 84 (67.2%) 4- Severe 41 (32.8%) Mean ± SD 3.33 ± 0.47 Median (P25, P75) 3.00 (3.00, 4.00) Min, Max 3.00, 4.00 Week 1, n (%) 1- Almost Clear 1 (0.8%) 2- Mild 15 (12.5%) 3- Moderate 83 (69.2%) 4- Severe 21 (17.5%) Mean ± SD 3.03 ± 0.58 Median (P25, P75) 3.00 (3.00, 3.00) Min, Max 1.00, 4.00 Missing values 5 ISGA of 0 (Clear) or 1 (Almost Clear), n (%) 1 (0.8%) Change from Baseline to Week 1, n (%) N 120 Mean ± SD ± 0.51 Median (P25, P75) 0.00 (-1.00, 0.00) Min, Max -2.00, 0.00 Missing values 5 At least one-grade improvement, n (%) 32 (26.7%) At least two-grade improvement, n (%) 3 (2.5%) Week 2, n (%) 1- Almost Clear 2 (1.7%) 2- Mild 27 (22.3%) 3- Moderate 77 (63.6%) 4- Severe 15 (12.4%) Mean ± SD 2.87 ± 0.63 Median (P25, P75) 3.00 (3.00, 3.00) Min, Max 1.00, 4.00 Missing values 4 ISGA of 0 (Clear) or 1 (Almost Clear), n (%) 2 (1.7%) STIEFEL CONFIDENTIAL Page 25

87 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 6.rtf Program: U Table 6.sas Source: Datasets EF_BSL & EF_VISITS Table 6: Investigator Static Global Assessment (Continued) ITT Analysis Set Total (n = 125) Change from Baseline to Week 2, n (%) N 121 Mean ± SD ± 0.61 Median (P25, P75) 0.00 (-1.00, 0.00) Min, Max -2.00, 1.00 Missing values 4 At least one-grade improvement, n (%) 50 (41.3%) At least two-grade improvement, n (%) 6 (5.0%) Week 4, n (%) 1- Almost Clear 4 (3.3%) 2- Mild 40 (33.3%) 3- Moderate 65 (54.2%) 4- Severe 11 (9.2%) Mean ± SD 2.69 ± 0.68 Median (P25, P75) 3.00 (2.00, 3.00) Min, Max 1.00, 4.00 Missing values 5 ISGA of 0 (Clear) or 1 (Almost Clear), n (%) 4 (3.3%) Change from Baseline to Week 4, n (%) N 120 Mean ± SD ± 0.69 Median (P25, P75) (-1.00, 0.00) Min, Max -3.00, 0.00 Missing values 5 At least one-grade improvement, n (%) 63 (52.5%) At least two-grade improvement, n (%) 12 (10.0%) STIEFEL CONFIDENTIAL Page 26

88 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 7.1: Post-Inflammatory Hyperpigmentation Assessments Severity ITT Analysis Set Output: U Table 7.rtf Program: U Table 7.sas Source: Datasets EF_BSL & EF_VISITS Total (n = 125) Baseline (Day 1), n (%) 0- Absent 51 (40.8%) 1- Slight 15 (12.0%) 2- Mild 41 (32.8%) 3- Moderate 17 (13.6%) 4- Moderately Severe 1 (0.8%) Mean ± SD 1.22 ± 1.15 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 4.00 Week 1, n (%) 0- Absent 47 (39.2%) 1- Slight 18 (15.0%) 2- Mild 40 (33.3%) 3- Moderate 15 (12.5%) Mean ± SD 1.19 ± 1.09 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 5 Change from Baseline to Week 1, n (%) N 120 Mean ± SD ± 0.35 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -2.00, 1.00 Missing values 5 Week 2, n (%) 0- Absent 50 (41.3%) 1- Slight 19 (15.7%) 2- Mild 36 (29.8%) 3- Moderate 16 (13.2%) Mean ± SD 1.15 ± 1.11 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 4 STIEFEL CONFIDENTIAL Page 27

89 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 7.1: Post-Inflammatory Hyperpigmentation Assessments (Continued) Severity ITT Analysis Set Output: U Table 7.rtf Program: U Table 7.sas Source: Datasets EF_BSL & EF_VISITS Total (n = 125) Change from Baseline to Week 2, n (%) N 121 Mean ± SD ± 0.58 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -2.00, 3.00 Missing values 4 Week 4, n (%) 0- Absent 52 (43.3%) 1- Slight 21 (17.5%) 2- Mild 34 (28.3%) 3- Moderate 12 (10.0%) 4- Moderately Severe 1 (0.8%) Mean ± SD 1.08 ± 1.09 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 4.00 Missing values 5 Change from Baseline to Week 4, n (%) N 120 Mean ± SD ± 0.51 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -2.00, 2.00 Missing values 5 STIEFEL CONFIDENTIAL Page 28

90 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 7.2: Post-Inflammatory Hyperpigmentation Assessments Distribution ITT Analysis Set Output: U Table 7.rtf Program: U Table 7.sas Source: Datasets EF_BSL & EF_VISITS Total (n = 125) Baseline (Day 1), n (%) 0- None 54 (43.2%) % of the face 27 (21.6%) % of the face 32 (25.6%) % of the face 11 (8.8%) % of the face 1 (0.8%) Mean ± SD 1.02 ± 1.06 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 4.00 Week 1, n (%) 0- None 51 (42.5%) % of the face 28 (23.3%) % of the face 30 (25.0%) % of the face 11 (9.2%) Mean ± SD 1.01 ± 1.02 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 5 Change from Baseline to Week 1, n (%) N 120 Mean ± SD ± 0.27 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -1.00, 1.00 Missing values 5 Week 2, n (%) 0- None 55 (45.5%) % of the face 26 (21.5%) % of the face 29 (24.0%) % of the face 11 (9.1%) Mean ± SD 0.97 ± 1.03 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 4 STIEFEL CONFIDENTIAL Page 29

91 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 7.2: Post-Inflammatory Hyperpigmentation Assessments (Continued) Distribution ITT Analysis Set Output: U Table 7.rtf Program: U Table 7.sas Source: Datasets EF_BSL & EF_VISITS Total (n = 125) Change from Baseline to Week 2, n (%) N 121 Mean ± SD ± 0.32 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -1.00, 1.00 Missing values 4 Week 4, n (%) 0- None 55 (45.8%) % of the face 31 (25.8%) % of the face 24 (20.0%) % of the face 10 (8.3%) Mean ± SD 0.91 ± 1.00 Median (P25, P75) 1.00 (0.00, 2.00) Min, Max 0.00, 3.00 Missing values 5 Change from Baseline to Week 4, n (%) N 120 Mean ± SD ± 0.38 Median (P25, P75) 0.00 (0.00, 0.00) Min, Max -2.00, 1.00 Missing values 5 STIEFEL CONFIDENTIAL Page 30

92 Stiefel, a GSK company MaxClarity Clinical Study Report U Output: U Table 8.rtf Program: U Table 8.sas Source: Dataset EF_VISITS Table 8: Subject's Global Improvement Scale ITT Analysis Set Total (n = 125) Week 1, n (%) 0- Worse 8 (6.7%) 1- Same 15 (12.5%) 2- Mild Improvement 76 (63.3%) 3- Obvious Improvement 17 (14.2%) 4- Marked Improvement 4 (3.3%) Mean ± SD 1.95 ± 0.82 Median (P25, P75) 2.00 (2.00, 2.00) Min, Max 0.00, 4.00 Missing values 5 Week 2, n (%) 0- Worse 3 (2.5%) 1- Same 23 (19.0%) 2- Mild Improvement 61 (50.4%) 3- Obvious Improvement 30 (24.8%) 4- Marked Improvement 4 (3.3%) Mean ± SD 2.07 ± 0.82 Median (P25, P75) 2.00 (2.00, 3.00) Min, Max 0.00, 4.00 Missing values 4 Week 4, n (%) 0- Worse 4 (3.3%) 1- Same 11 (9.2%) 2- Mild Improvement 61 (50.8%) 3- Obvious Improvement 36 (30.0%) 4- Marked Improvement 8 (6.7%) Mean ± SD 2.28 ± 0.85 Median (P25, P75) 2.00 (2.00, 3.00) Min, Max 0.00, 4.00 Missing values 5 STIEFEL CONFIDENTIAL Page 31

93 Stiefel, a GSK company MaxClarity Clinical Study Report U Quality of Life and Patient Preference Data Tables presenting adverse event data are pending full completion of the study. Table Number Table 9 Table Title Subject s Preference Post-Study Questionnaire ITT Analysis Set STIEFEL CONFIDENTIAL Page 32

94 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 9: Subject s Preference Post-Study Questionnaire ITT Analysis Set This table will be produced for the final statistical analysis. STIEFEL CONFIDENTIAL Page 33

95 Stiefel, a GSK company MaxClarity Clinical Study Report U Safety Data Tables presenting adverse event data are pending full completion of the study. Table Number Table 10.1 Table 10.2 Table 10.3 Table 10.4 Table 10.5 Table 10.6 Table 11 Table Title Incidence of Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set Incidence of Treatment-Emergent Adverse Events Classified by Preferred Term in Descending Order of Frequency ITT Analysis Set Incidence of Treatment-Related Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set Incidence of Severe Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set Incidence of Treatment-Emergent Adverse Events Resulting in Discontinuation Classified by System Organ Class and Preferred Term ITT Analysis Set Incidence of Serious Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set Prevalence of Concomitant Medication Use Classified by 2nd ATC level and Preferred Term ITT Analysis Set STIEFEL CONFIDENTIAL Page 34

96 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.1: Incidence of Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set Total (n = 125) SYSTEM ORGAN CLASS N (%) Preferred Term SUBJECTS REPORTING ANY ADVERSE EVENT 11 (8.8%) GASTROINTESTINAL DISORDERS 1 (0.8%) GASTROOESOPHAGEAL REFLUX DISEASE 1 (0.8%) IMMUNE SYSTEM DISORDERS 1 (0.8%) SEASONAL ALLERGY 1 (0.8%) INFECTIONS AND INFESTATIONS 6 (4.8%) NASOPHARYNGITIS 3 (2.4%) ORAL HERPES 2 (1.6%) PHARYNGITIS STREPTOCOCCAL 1 (0.8%) SINUSITIS 1 (0.8%) UPPER RESPIRATORY TRACT INFECTION 1 (0.8%) VULVOVAGINAL MYCOTIC INFECTION 1 (0.8%) INJURY, POISONING AND PROCEDURAL COMPLICATIONS 1 (0.8%) CONTUSION 1 (0.8%) NERVOUS SYSTEM DISORDERS 1 (0.8%) BURNING SENSATION 1 (0.8%) REPRODUCTIVE SYSTEM AND BREAST DISORDERS 1 (0.8%) OVARIAN CYST 1 (0.8%) RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS 1 (0.8%) RHINITIS ALLERGIC 1 (0.8%) SKIN AND SUBCUTANEOUS TISSUE DISORDERS 1 (0.8%) RASH 1 (0.8%) Subjects reporting a particular adverse event more than once are counted only once for that adverse event Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 35

97 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.2: Incidence of Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term in Descending Order of Frequency ITT Analysis Set Total (n = 125) PREFERRED TERM N (%) SUBJECTS REPORTING ANY ADVERSE EVENT 11 (8.8%) NASOPHARYNGITIS 3 (2.4%) ORAL HERPES 2 (1.6%) BURNING SENSATION 1 (0.8%) CONTUSION 1 (0.8%) GASTROOESOPHAGEAL REFLUX DISEASE 1 (0.8%) OVARIAN CYST 1 (0.8%) PHARYNGITIS STREPTOCOCCAL 1 (0.8%) RASH 1 (0.8%) RHINITIS ALLERGIC 1 (0.8%) SEASONAL ALLERGY 1 (0.8%) SINUSITIS 1 (0.8%) UPPER RESPIRATORY TRACT INFECTION 1 (0.8%) VULVOVAGINAL MYCOTIC INFECTION 1 (0.8%) Subjects reporting a particular adverse event more than once are counted only once for that adverse event Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 36

98 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.3: Incidence of Treatment-Related Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set No Treatment-Related Adverse Event was reported during the Study. Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 37

99 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.4: Incidence of Severe Treatment-Emergent Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set Total (n = 125) SYSTEM ORGAN CLASS N (%) Preferred Term SUBJECTS REPORTING ANY ADVERSE EVENT 1 (0.8%) INFECTIONS AND INFESTATIONS 1 (0.8%) UPPER RESPIRATORY TRACT INFECTION 1 (0.8%) Subjects reporting a particular adverse event more than once are counted only once for that adverse event Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 38

100 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.5: Incidence of Treatment-Emergent Adverse Events Resulting in Discontinuation Classified by System Organ Class and Preferred Term ITT Analysis Set Total (n = 125) SYSTEM ORGAN CLASS N (%) Preferred Term SUBJECTS REPORTING ANY ADVERSE EVENT 1 (0.8%) SKIN AND SUBCUTANEOUS TISSUE DISORDERS 1 (0.8%) RASH 1 (0.8%) Subjects reporting a particular adverse event more than once are counted only once for that adverse event Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 39

101 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 10.6: Incidence of Serious Adverse Events Classified by System Organ Class and Preferred Term ITT Analysis Set No Serious Adverse Event was reported during the Study. Output: U Table 10.rtf Program: U Table 10.sas Source: Dataset AE STIEFEL CONFIDENTIAL Page 40

102 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 11: Prevalence of Concomitant Medication Use Classified by 2nd ATC Level and Preferred Term ITT Analysis Set Total (n = 125) DRUG CLASSIFICATION N (%) Medication ADRENERGICS AND OTH.DRUGS FOR OBSTRUCT.AIRWAY DIS. 1 (0.8%) Seretide 1 (0.8%) AMINOALKYL ETHERS 4 (3.2%) Diphenhydramine 4 (3.2%) ANILIDES 5 (4.0%) Benadryl cold and flu 1 (0.8%) Pamprin 1 (0.8%) Paracetamol 2 (1.6%) Thomapyrin n 1 (0.8%) ANTIALLERGIC AGENTS, EXCL. CORTICOSTEROIDS 1 (0.8%) Olopatadine 1 (0.8%) ANTIINFECTIVES FOR TREATMENT OF ACNE 1 (0.8%) Clindamycin 1 (0.8%) ANTIVIRALS 1 (0.8%) Aciclovir 1 (0.8%) BETA BLOCKING AGENTS, SELECTIVE 2 (1.6%) Metoprolol 2 (1.6%) CALCIUM COMPOUNDS 1 (0.8%) Calcium carbonate 1 (0.8%) CARBAMIDE PRODUCTS 1 (0.8%) Urea 1 (0.8%) CENTRALLY ACTING SYMPATHOMIMETICS 6 (4.8%) Lisdexamfetamine 1 (0.8%) Methylphenidate 3 (2.4%) Obetrol 2 (1.6%) COMB OF PENICILLINS, INCL. BETA-LACTAMASE INHIB. 1 (0.8%) Augmentin 1 (0.8%) COMB.SULFONAMIDES & TRIMETHOPRIM INCL. DERIVATIVES 1 (0.8%) Bactrim 1 (0.8%) CORTICOSTEROIDS 2 (1.6%) Fluticasone 2 (1.6%) CORTICOSTEROIDS, POTENT (GROUP III) 2 (1.6%) Betamethasone 1 (0.8%) Fluocinonide 1 (0.8%) CORTICOSTEROIDS, VERY POTENT (GROUP IV) 1 (0.8%) Clobetasol 1 (0.8%) Subjects reporting a particular concomitant medication more than once are counted only once for that drug Output: U Table 11.rtf Program: U Table 11.sas Source: Dataset CM STIEFEL CONFIDENTIAL Page 41

103 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 11: Prevalence of Concomitant Medication Use (Continued) Classified by 2nd ATC Level and Preferred Term ITT Analysis Set Total (n = 125) DIPHENYLMETHANE DERIVATIVES 1 (0.8%) Hydroxyzine 1 (0.8%) EXPECTORANTS 1 (0.8%) Guaifenesin 1 (0.8%) GLUCOCORTICOIDS 1 (0.8%) Fluticasone 1 (0.8%) H2-RECEPTOR ANTAGONISTS 1 (0.8%) Famotidine 1 (0.8%) IMIDAZOLE AND TRIAZOLE DERIVATIVES 1 (0.8%) Ketoconazole 1 (0.8%) IMIDAZOLE DERIVATIVES 1 (0.8%) Miconazole 1 (0.8%) INSULINS AND ANALOGUES 1 (0.8%) Insulin 1 (0.8%) INTRAUTERINE CONTRACEPTIVES 2 (1.6%) Intrauterine contraceptive device 2 (1.6%) INTRAVAGINAL CONTRACEPTIVES 10 (8.0%) Intravaginal contraceptives 10 (8.0%) MACROLIDES 1 (0.8%) Azithromycin 1 (0.8%) MULTIVITAMINS WITH MINERALS 1 (0.8%) Multivitamins plus iron 1 (0.8%) MULTIVITAMINS, PLAIN 10 (8.0%) Multivitamin 10 (8.0%) NATURAL OPIUM ALKALOIDS 2 (1.6%) Panadeine co 1 (0.8%) Vicodin 1 (0.8%) OTHER ANTIDEPRESSANTS 2 (1.6%) Trazodone 2 (1.6%) OTHER ANTIEPILEPTICS 1 (0.8%) Lamotrigine 1 (0.8%) Zonisamide 1 (0.8%) OTHER ANTIFUNGALS FOR TOPICAL USE 1 (0.8%) Naftifine 1 (0.8%) OTHER ANTIHISTAMINES FOR SYSTEMIC USE 3 (2.4%) Fexofenadine 2 (1.6%) Loratadine 1 (0.8%) Subjects reporting a particular concomitant medication more than once are counted only once for that drug Output: U Table 11.rtf Program: U Table 11.sas Source: Dataset CM STIEFEL CONFIDENTIAL Page 42

104 Stiefel, a GSK company MaxClarity Clinical Study Report U Table 11: Prevalence of Concomitant Medication Use (Continued) Classified by 2nd ATC Level and Preferred Term ITT Analysis Set Total (n = 125) OTHER EMOLLIENTS AND PROTECTIVES 2 (1.6%) Dimeticone 1 (0.8%) Other emollients and protectives 1 (0.8%) OTHER LIPID MODIFYING AGENTS 1 (0.8%) Fish oil 1 (0.8%) OTHER NASAL PREPARATIONS 1 (0.8%) Sodium chloride 1 (0.8%) OTHER PLAIN VITAMIN PREPARATIONS 1 (0.8%) Biotin 1 (0.8%) OXICAMS 1 (0.8%) Meloxicam 1 (0.8%) PENICILLINS WITH EXTENDED SPECTRUM 1 (0.8%) Amoxicillin 1 (0.8%) PIPERAZINE DERIVATIVES 6 (4.8%) Cetirizine 6 (4.8%) PREPARATIONS CONTAINING SULFUR 1 (0.8%) Rosula 1 (0.8%) PROGESTOGENS AND ESTROGENS, FIXED COMBINATIONS 9 (7.2%) Anovlar 2 (1.6%) Cilest 4 (3.2%) Drospirenone w/ethinylestradiol 1 (0.8%) Eugynon 1 (0.8%) Norlestrin fe 1 (0.8%) PROPIONIC ACID DERIVATIVES 6 (4.8%) Ibuprofen 5 (4.0%) Naproxen 1 (0.8%) SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS 4 (3.2%) Salbutamol 4 (3.2%) SELECTIVE SEROTONIN REUPTAKE INHIBITORS 4 (3.2%) Citalopram 2 (1.6%) Fluoxetine 1 (0.8%) Paroxetine 1 (0.8%) SYMPATHOMIMETICS 1 (0.8%) Pseudoephedrine 1 (0.8%) UNSPECIFIED HERBAL 2 (1.6%) Herbal preparation 2 (1.6%) Subjects reporting a particular concomitant medication more than once are counted only once for that drug Output: U Table 11.rtf Program: U Table 11.sas Source: Dataset CM STIEFEL CONFIDENTIAL Page 43

105 Stiefel, a GSK company MaxClarity Clinical Study Report U Protocol and Protocol Amendments STIEFEL CONFIDENTIAL Page 44

106 Stiefel, a GSK company Clinical Study Protocol U , Version 1.0 An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the MaxClarity System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne Clinical Study Protocol: U (STF115576) Version 1.0: 17 March 2011 Sponsored by: Stiefel, a GSK company 20 TW Alexander Drive Research Triangle Park, NC THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE LICENSING AND/OR REGISTRATION OF PRODUCTS FOR STIEFEL OR ITS AFFILIATED COMPANIES. THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN WHOLE OR IN PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF STIEFEL. STIEFEL CONFIDENTIAL 1

Tolerance of a Low-Level Blue and Red Light Therapy Acne Mask in Acne Patients with Sensitive Skin

Tolerance of a Low-Level Blue and Red Light Therapy Acne Mask in Acne Patients with Sensitive Skin Poster 7098 Tolerance of a Low-Level Blue and Red Light Therapy Acne Mask in Acne Patients with Sensitive Skin Dara Miller 1, Michael J. Cohen 1, Adegboyega Adenaike 1, Julie Biron 2, Michael H. Gold,

More information

SPECIAL TOPIC. Virginia Clinical Research, Inc., Norfolk, VA b. Oregon Dermatology and Research Center, Portland, OR c

SPECIAL TOPIC. Virginia Clinical Research, Inc., Norfolk, VA b. Oregon Dermatology and Research Center, Portland, OR c September 2014 611 Volume 13 Issue 9 Copyright 2014 ORIGINAL ARTICLES Journal of Drugs in Dermatology SPECIAL TOPIC An Aqueous Gel Fixed Combination of Clindamycin Phosphate 1.2% and Benzoyl Peroxide 3.75%

More information

A novel daily moisturizing cream for effective management of mild to moderate Atopic Dermatitis in infants and children

A novel daily moisturizing cream for effective management of mild to moderate Atopic Dermatitis in infants and children TM Weber PhD 1, F Samarin MD 3, M Babcock MD 2, A Filbry PhD 4, C Arrowitz 1, F Rippke MD 4 1 Beiersdorf Inc., Wilton CT, USA 2 Mountaintop Dermatology, Colorado Springs CO, USA 3 Colorado Springs Dermatology

More information

PDF of Trial CTRI Website URL -

PDF of Trial CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Fri, 21 Dec 2018 19:27:12 GMT) CTRI Number Last Modified On 06/01/2014 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

The secondary objective was to evaluate the cosmetic properties and its efficacy after 28 days.

The secondary objective was to evaluate the cosmetic properties and its efficacy after 28 days. P0090 CLINICAL EVALUATION OF CUTANEOUS SAFETY AND EFFICACY OF A FACE EMULSION CONTAINING MYRTACIN EXTRACT, PP VITAMIN ANS SABAL EXTRACT ON ACNE PRONE SKIN SUBJECTS TREATED BY TOPICAL ANTI ACNE DRUG THERAPY.

More information

PDF of Trial CTRI Website URL -

PDF of Trial CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Tue, 02 Oct 2018 21:40:33 GMT) CTRI Number Last Modified On 26/12/2012 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

CLINICAL EVALUATION OF REVIVOGEN TOPICAL FORMULA FOR TREATMENT OF MEN AND WOMEN WITH ANDROGENETIC ALOPECIA. A PILOT STUDY

CLINICAL EVALUATION OF REVIVOGEN TOPICAL FORMULA FOR TREATMENT OF MEN AND WOMEN WITH ANDROGENETIC ALOPECIA. A PILOT STUDY CLINICAL EVALUATION OF REVIVOGEN TOPICAL FORMULA FOR TREATMENT OF MEN AND WOMEN WITH ANDROGENETIC ALOPECIA. A PILOT STUDY Alex Khadavi, MD, et al,. Los Angeles, CA USA 2004 Abstract: This study was done

More information

New Patient Registration

New Patient Registration New Patient Registration Today s Date: Social Security Number: Name: Last First MIddle How do you like to be addressed: Date of Birth: Address: Street City State Zip Email Address: Preferred Contact Number:

More information

JDDonline.com. Introduction. Methods Study Design Twenty-three patients enrolled in a 4-week, multicenter, investigator-blinded,

JDDonline.com. Introduction. Methods Study Design Twenty-three patients enrolled in a 4-week, multicenter, investigator-blinded, 534 Emil Tanghetti MD, a Leon Kircik MD, b David Wilson MD, c Sunil Dhawan MD d a. Center for Dermatology and Laser Surgery, Sacramento, CA b. Physicians Skin Care PLLC, Louisville, KY c. Education and

More information

Management of acne requires proper application

Management of acne requires proper application DRUG THERAPY TOPICS A Qualitative and Quantitative Assessment of the Application and Use of Topical Acne Medication by Patients James Q. Del Rosso, DO Management of acne requires proper application of

More information

POLYTAR Plus Liquid PRODUCT INFORMATION. Polytar Plus Liquid medicated scalp cleanser, contains coal tar solution.

POLYTAR Plus Liquid PRODUCT INFORMATION. Polytar Plus Liquid medicated scalp cleanser, contains coal tar solution. NAME OF THE MEDICINE POLYTAR Plus Liquid PRODUCT INFORMATION Polytar Plus Liquid medicated scalp cleanser, contains coal tar solution. DESCRIPTION Polytar Plus Liquid contains coal tar solution 4% w/w.

More information

East Hill Medical Group

East Hill Medical Group Name: of Birth: Address: City: State: Zip: Home Tel. #: Cell #: Employer: Occupation: Emergency Contact: Relationship: Phone: Email: How Referred: Parents Ethnic Background: Previous Treatments Year: Area(s):

More information

513 Maple Ave West, Vienna, VA

513 Maple Ave West, Vienna, VA CLIENT INFORMATION AND CONSENT FORM: SKIN CARE Name Date of Consultation Address City State Zip Home phone ( ) Cellular phone ( ) E-mail Date of birth Emergency contact and telephone number How did you

More information

MULTICENTER CLINICAL AND INSTRUMENTAL STUDY FOR THE EVALUATION OF EFFICACY AND TOLERANCE OF AN INTRADERMAL INJECTABLE PRODUCT AS A FILLER AND A

MULTICENTER CLINICAL AND INSTRUMENTAL STUDY FOR THE EVALUATION OF EFFICACY AND TOLERANCE OF AN INTRADERMAL INJECTABLE PRODUCT AS A FILLER AND A MULTICENTER CLINICAL AND INSTRUMENTAL STUDY FOR THE EVALUATION OF EFFICACY AND TOLERANCE OF AN INTRADERMAL INJECTABLE PRODUCT AS A FILLER AND A BIOREVITALIZER FOR THE AGING FACE PURPOSE Aim of the study

More information

Personal Profile and Health History

Personal Profile and Health History --CAPITAL AESTHETICS Personal Profile and Health History Name: Home Phone: Address: Work Phone: City/State/Zip: Date of Birth: Age: Gender: M F Occupation: Email address: How did you hear about us? What

More information

Title: A randomised, assessor blind, parallel group comparative efficacy trial of three head lice treatments in children

Title: A randomised, assessor blind, parallel group comparative efficacy trial of three head lice treatments in children Author's response to reviews Title: A randomised, assessor blind, parallel group comparative efficacy trial of three head lice treatments in children Authors: Stephen C Barker (s.barker@uq.edu.au) Phillip

More information

MANNATECH SKIN CARE PRODUCT SAFETY AND EFFICACY TESTING

MANNATECH SKIN CARE PRODUCT SAFETY AND EFFICACY TESTING MANNATECH SKIN CARE PRODUCT SAFETY AND EFFICACY TESTING The Food, Drug & Cosmetics Act does not require that cosmetics be tested for safety. The U.S. Food and Drug Administration (FDA) does advise cosmetic

More information

TEOSYAL PEN: Personal experience after 12 months on 285 consecutive patients

TEOSYAL PEN: Personal experience after 12 months on 285 consecutive patients TEOSYAL PEN: Personal experience after 12 months on 285 consecutive patients Dr. Dell Avanzato Roberto AMWC 2016, 14 th Aesthetic & Anti-aging Medicine World Congress 31 March, 1 2 April, 2016 BACKGROUND

More information

Lisa Chipps, MD, MS, FAAD Assistant Clinical Professor David Geffen School of Medicine at UCLA

Lisa Chipps, MD, MS, FAAD Assistant Clinical Professor David Geffen School of Medicine at UCLA Lisa Chipps, MD, MS, FAAD Assistant Clinical Professor David Geffen School of Medicine at UCLA Presented at The American Academy of Facial Plastic and Reconstructive Surgery Meeting, September, 2011 Provided

More information

TACTUPUMP. TACTUPUMP FORTE adapalene and benzoyl peroxide topical gel, 0.3%/2.5% w/w

TACTUPUMP. TACTUPUMP FORTE adapalene and benzoyl peroxide topical gel, 0.3%/2.5% w/w PRODUCT MONOGRAPH Pr TACTUPUMP adapalene and benzoyl peroxide topical gel, 0.1%/2.5% w/w TACTUPUMP FORTE adapalene and benzoyl peroxide topical gel, 0.3%/2.5% w/w Acne Therapy GALDERMA CANADA INC. 55 Commerce

More information

THE REPORT FROM APPLICATION TEST RESEARCH OF COSMETICAL PRODUCT

THE REPORT FROM APPLICATION TEST RESEARCH OF COSMETICAL PRODUCT THE REPORT FROM APPLICATION TEST RESEARCH OF COSMETICAL PRODUCT Product Responsible Person LIFT4SKIN Instant smoothing serum Oceanic S.A. ul. Łokietka 58 81-736 Sopot Report number B-0936/16 Issue date

More information

Maya Med Spa 6330 Broadway Blvd. Suite B, Garland, TX Name: Date of birth: Address: Pharmacy of your choice:

Maya Med Spa 6330 Broadway Blvd. Suite B, Garland, TX Name: Date of birth: Address: Pharmacy of your choice: Client Consultation Name: Date of birth: Address: Home Phone: Cell Phone: Business Phone: E-mail address: Married: Yes No If yes, anniversary date: Employer: Occupation: Pharmacy of your choice: Does your

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. TOPICAL RETINOID AND COMBINATION PRODUCTS: ATRALIN (tretinoin) gel AVITA (tretinoin) cream and gel DIFFERIN (adapalene) cream, gel, lotion (Over-the-Counter Differin is a plan exclusion) EPIDUO (adapalene-benzoyl

More information

NIGHTTIME ANTIOXIDANT

NIGHTTIME ANTIOXIDANT NIGHTTIME ANTIOXIDANT CLINICAL RESULTS: RESVERATROL B E 12 WEEKS RESVERATROL B E IMPROVEMENT IN FIRMNESS, SMOOTHNESS, AND OVERALL RADIANCE 12-week clinical study conducted on 55 females ages 45-60 years

More information

Clinical studies with patients have been carried out on this subject of graft survival and out of body time. They are:

Clinical studies with patients have been carried out on this subject of graft survival and out of body time. They are: Study Initial Date: July 21, 2016 Data Collection Period: Upon CPHS Approval to September 30, 2018 Study Protocol: Comparison of Out of Body Time of Grafts with the Overall Survival Rates using FUE Lead

More information

4.3. Contraindications Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

4.3. Contraindications Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Tactuo 0.1% / 2.5% gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g of gel contains: Adapalene 1 mg (0.1 %) Benzoyl Peroxide 25 mg

More information

Results Clinical Photography

Results Clinical Photography A High-Strength Retinol Serum Enhanced with N-Acetyl Glucosamine Provides Significant Anti-Aging Effects in Combination with a Comprehensive Skincare Regimen Joel Schlessinger, MD ; Brenda L. Edison, BA

More information

AREA OF BODY TATTOO IS SITUATED?

AREA OF BODY TATTOO IS SITUATED? CLIENT CONSULTATION LASER TATTOO REMOVAL FORM Address: Date of Birth: Suburb: State: Postcode: Telephone: Work: Mobile Home: Other: Email Address: How did you hear about us? Tattoo Removal Colours in tattoo

More information

CHEMICAL SKIN PEELING

CHEMICAL SKIN PEELING CLIENT REF DATE OF TREATMENT The CIBTAC / SALLY DURANT Level 4 Qualifications in Advanced Skin Studies and Aesthetic Practice COMPETENCY ASSESSMENT CHEMICAL SKIN PEELING Student Name Candidate Number LEVEL

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Epiduo 0.3% / 2.5% gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of gel contains: adapalene 3 mg (0.3%) benzoyl peroxide 25

More information

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory DERMOCALM LOTION. Calamine and Light Liquid Paraffin Lotion

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory DERMOCALM LOTION. Calamine and Light Liquid Paraffin Lotion For the use only of Registered Medical Practitioners or a Hospital or a Laboratory DERMOCALM LOTION and Light Liquid Paraffin Lotion QUALITATIVE AND QUANTITATIVE COMPOSITION * IP Light Liquid Paraffin

More information

C_005 - Introduction to the Globally Harmonized System of Hazard Communication

C_005 - Introduction to the Globally Harmonized System of Hazard Communication C_005 - Introduction to the Globally Harmonized System of Hazard Communication Kenneth L. Marshall LLE Chemical Hygiene Officer 11/04/2013 S-SA-M-036 Rev. A - C_005 - Introduction to GHS.pptx 1 of 21 Summary

More information

HEDS Campus Climate Sexual Assault Survey. Occidental College and Other Schools

HEDS Campus Climate Sexual Assault Survey. Occidental College and Other Schools HEDS Campus Climate Sexual Assault Survey Occidental College and Other Schools OFFICE OF INSTITUTIONAL RESEARCH, ASSESSMENT AND PLANNING (IRAP) TITLE IX OFFICE SEPTEMBER 2015 About the Survey (Administered

More information

ENERPEEL SPECIALIST IN PEELS. Advanced Chemical Peel Systems for younger, healthier looking skin

ENERPEEL SPECIALIST IN PEELS. Advanced Chemical Peel Systems for younger, healthier looking skin ENERPEEL SPECIALIST IN PEELS Advanced Chemical Peel Systems for younger, healthier looking skin PROFESSIONAL Modern Approach to Exfoliation MAXIMIZE RESULTS MINIMIZE DOWNTIME STRONG EFFICACY BETTER TOLERABILITY

More information

Client Questionnaire Skin & Health

Client Questionnaire Skin & Health Client Questionnaire Skin & Health Please answer the following questions thoroughly and completely, as this provides a better understanding of your general health, lifestyle and skin care concerns; thereby

More information

SRL : FINAL REPORT March 22, EF Expected Static SPF 20. Non-randomized, with blinded evaluations

SRL : FINAL REPORT March 22, EF Expected Static SPF 20. Non-randomized, with blinded evaluations 2518-B Reynolda Road Winston Salem. NC 27106 USA (336)725-6503 fax vwfw.suncalelab.com jstanfield.dsuncalelal).com : FINAL REPORT March 22, 2010 Title: Objective: Test Product: Study Design: Study Dates:

More information

Client Intake Form. Name: Date: Address: City: ST: Zip: Phone:

Client Intake Form. Name: Date: Address: City: ST: Zip:   Phone: Client Intake Form Name: Date: Last First Address: City: ST: Zip: Email: Phone: How did you hear about Skin Renew Day Spa? What are your main concerns? How long have you been experiencing your current

More information

1

1 www.trichosciencepro.com 1 TrichoSciencePro Professional hair and scalp diagnostic software PRESENTATION The latest program version of TrichoSciencePro version 1.3SE was released in 2015 and has numerous

More information

FACT SHEET: ISOTRETINOIN INFORMATION FOR PATIENTS

FACT SHEET: ISOTRETINOIN INFORMATION FOR PATIENTS FACT SHEET: ISOTRETINOIN INFORMATION FOR PATIENTS You have been prescribed isotretinoin (=Roaccutane, Oratane) for your acne. It is used for acne which does not respond to other treatments, scarring and

More information

Hair To Bare South. Client Name: Date:

Hair To Bare South. Client Name: Date: Hair To Bare South Client Name: Date: I authorize Rachelle Stokes (Hair To Bare South) to perform the treatments. The purpose of these treatments is to diminish or remove unwanted hair. The quantity of

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. TOPICAL CLINDAMYCIN PRODUCTS: ACANYA (clindamycin phosphate-benzoyl peroxide) gel BENZACLIN (clindamycin phosphate-benzoyl peroxide) gel CLEOCIN-T (clindamycin phosphate) gel, lotion, solution, swab CLINDAGEL

More information

designed to stimulate collagen

designed to stimulate collagen Discover the volumizer designed to stimulate collagen with results that last over 2 years* Elaine: Age 40 (2.5 vials) Christine: Age 39 (2 vials) Veronica: Age 33 (4 vials) Actual Sculptra Aesthetic patients

More information

Patients should be given information about skin reactions and self-care strategies. A recent UK survey found that:

Patients should be given information about skin reactions and self-care strategies. A recent UK survey found that: Summary of Interventions for Acute Radiotherapy-Induced Skin Reactions in Cancer Patients: A Clinical Guideline recommended for use by The Society and; College of Radiographers Responsible person: Rachel

More information

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BREVOXYL CREAMY WASH. Benzoyl Peroxide Creamy Wash 4%

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BREVOXYL CREAMY WASH. Benzoyl Peroxide Creamy Wash 4% For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BREVOXYL CREAMY WASH Benzoyl Peroxide Creamy Wash 4% QUALITATIVE AND QUANTITATIVE COMPOSITION Hydrous Benzoyl Peroxide

More information

Evaluation of an Experimental Hydrogen Peroxide Post Milking Teat Dip on Teat End and Teat Skin Condition and Health

Evaluation of an Experimental Hydrogen Peroxide Post Milking Teat Dip on Teat End and Teat Skin Condition and Health Animal Industry Report AS 657 ASL R2603 2011 Evaluation of an Experimental Hydrogen Peroxide Post Milking Teat Dip on Teat End and Teat Skin Condition and Health Jesse Juarez Iowa State University Leo

More information

Chemical Peels Corporate Medical Policy

Chemical Peels Corporate Medical Policy Chemical Peels Corporate Medical Policy File Name: Chemical Peels File Code: UM.SURG.13 Origination: 08/2016 Last Review: 10/2018 Next Review: 10/2019 Effective Date: 01/01/2019 Description/Summary A chemical

More information

Assessment Record. VTCT Level 4 Certificate in. Enhancing Eyebrows with. Microblading Techniques BT4C2. Learner name: Learner number: 603/1305/5

Assessment Record. VTCT Level 4 Certificate in. Enhancing Eyebrows with. Microblading Techniques BT4C2. Learner name: Learner number: 603/1305/5 Assessment Record Learner name: Learner number: BT4C2 VTCT Level 4 Certificate in Enhancing Eyebrows with Microblading Techniques 603/1305/5 BT4C2F_v2 Qualification at a glance This is an Assessment Record

More information

Aesthetic Patient Form

Aesthetic Patient Form Aesthetic Patient Form Name: Date: Address: City: State: Zip: Home Phone: Work Phone: Cell: Age: Date of Birth: Occupation: Email: FITZPATRICK CLASSIFICATION SYSTEM: Please select the skin type that seems

More information

Clear Proof Acne System

Clear Proof Acne System Clear Proof Acne System What You Should Know About Clear Proof Acne System: What products are in the regimen. What is the regimen Power Statement. What results did people see. What did people have to say

More information

Imagining the future of beauty

Imagining the future of beauty RESEARCH AND DEVELOPMENT Imagining the future of beauty Some 3,000 people work in L Oréal s twelve research centres in the four corners of the world. Their mission: to understand the skin and hair of men

More information

Contact Information. Idaho Falls. Idaho Falls, ID (208) (307) NAME. City / state / zip

Contact Information. Idaho Falls. Idaho Falls, ID (208) (307) NAME. City / state / zip Contact Information NAME physical street address City / state / zip Home phone cell phone email address want monthly specials? date of birth Age gender Male female How did you hear about us? WHICH AREAS

More information

Newport Cosmetic Center

Newport Cosmetic Center Shirin Afrasiabi, M.D, Inc. 2301 Newport Blvd, Costa Mesa, Ca 92627 (949) 548-5700 Appointment: Initial. We require a valid Credit Card at the time of booking to secure your appointment Cancellation and

More information

EVALUATION OF KNOWLEDGE OF TOOTH BLEACHING AMONG PATIENTS-A QUESTIONNARE BASED STUDY

EVALUATION OF KNOWLEDGE OF TOOTH BLEACHING AMONG PATIENTS-A QUESTIONNARE BASED STUDY International Journal of Research in Social Sciences Vol. 7 Issue 7, July 2017, ISSN: 2249-2496 Impact Factor: 7.081 Journal Homepage: Double-Blind Peer Reviewed Refereed Open Access International Journal

More information

Provide colour correction services

Provide colour correction services Provide colour correction services D/600/1010 Learner name: Learner number: VTCT is the specialist awarding body for the Hairdressing, Beauty Therapy, Complementary Therapy and Sport and Active Leisure

More information

Areas of Concern. Patient s Name Last First Date

Areas of Concern. Patient s Name Last First Date Areas of Concern What are your main concerns for today s visit? Please check the problem areas that concern you. Include anything you wish to discuss, even if it is not the main reason for your visit.

More information

Patient Information. M.I. Address: DOB: Sex: M F City: State: Zip: Social Security Number: / / Whom may we thank for referring you?

Patient Information. M.I. Address: DOB: Sex: M F City: State: Zip: Social Security Number: / / Whom may we thank for referring you? Today's : First Name M.I. Address: DOB: Sex: M F City: State: Zip: Social Security Number: / / Home Phone: ( ) Work Phone: ( ) Cell Phone: ( ) Patient Information Last Name Email: Primary Care Physican:

More information

Children s Hospital Of Wisconsin

Children s Hospital Of Wisconsin Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,

More information

INFORMED CHEMICAL PEEL CONSENT. 1. I authorize the chemical peel listed above, to my face and / or neck, chest and hands.

INFORMED CHEMICAL PEEL CONSENT. 1. I authorize the chemical peel listed above, to my face and / or neck, chest and hands. INFORMED CHEMICAL PEEL CONSENT 1. I authorize the chemical peel listed above, to my face and / or neck, chest and hands. 2. Depending on the chemical peel site, there may be redness and/or irritation and

More information

Informed Consent for Dermal Filler

Informed Consent for Dermal Filler Informed Consent for Dermal Filler NAME: DATE OF BIRTHG: ADDRESS: CELL PHONE: EMAIL: www.medicaleyecenter.com Please initial all of the following sections confirming that you have read and understand each

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Duac Once Daily 10 mg/g + 50 mg/g Gel 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g of gel contains: 10 mg clindamycin as clindamycin

More information

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory OILATUM EMOLLIENT. Light Liquid Paraffin Emollient

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory OILATUM EMOLLIENT. Light Liquid Paraffin Emollient For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory OILATUM EMOLLIENT Light Liquid Paraffin Emollient QUALITATIVE AND QUANTITATIVE COMPOSITION Light Liquid Paraffin IP Base

More information

Date: Date of Birth: Gender: Male Female. City: State: Zip: Caucasion a African-American Hispanic Asian East Indian American Indian

Date: Date of Birth: Gender: Male Female. City: State: Zip: Caucasion a African-American Hispanic Asian East Indian American Indian Contact Information: Date: Date of Birth: Gender: Male Female Name: Address: City: State: Zip: Home Phone: Work/Day Phone: Cell: Email: Emergency Contact: Emergency Contact Phone: Medical Background Ethnic

More information

Out With the Old and In With the New by Diane Molinaro, CPCP

Out With the Old and In With the New by Diane Molinaro, CPCP Out With the Old and In With the New by Diane Molinaro, CPCP W hat do we do when we have clients walk through our doors with double eyebrow tails, poorly placed pigment, pigment too dark to color correct

More information

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BREVOXYL HYDROPHASE. Benzoyl Peroxide Cream IP

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BREVOXYL HYDROPHASE. Benzoyl Peroxide Cream IP For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BREVOXYL HYDROPHASE Benzoyl Peroxide Cream IP QUALITATIVE AND QUANTITATIVE COMPOSITION Hydrous Benzoyl Peroxide IP equivalent

More information

EFFECTIVE PRIMARY CARE MANAGEMENT OF ACNE VULGARIS

EFFECTIVE PRIMARY CARE MANAGEMENT OF ACNE VULGARIS EFFECTIVE PRIMARY CARE MANAGEMENT OF ACNE VULGARIS WHY ACNE? EXCESS OIL PRODUCTION BY OVERACTIVE SEBACEOUS GLANDS. IMPROPER CELL TURNOVER/EXFOLIATION CLOGS PORES. DISRUPTED OXYGEN SUPPLY ALLOWS P. ACNE

More information

IN VIVO DETERMINATION OF THE SUN PROTECTION FACTOR (SPF) FINAL REPORT (COMPLEMENT OF PRELIMINARY ASSESSMENT NO /18/CGDA/1)

IN VIVO DETERMINATION OF THE SUN PROTECTION FACTOR (SPF) FINAL REPORT (COMPLEMENT OF PRELIMINARY ASSESSMENT NO /18/CGDA/1) REPORT OF ANALYSIS No. 215098/18/CGDA/2 Client Sample description (according to declaration of the Client) DermaPharm A/S Europavej 10 8990 Fårup SUN SPRAY SPF 30 Sample received: 18.05.2018 Recept: 40505108

More information

Arbonne Intelligence Genius Ultra

Arbonne Intelligence Genius Ultra Arbonne Intelligence Genius Ultra Arbonne Intelligence Genius Ultra Arbonne skincare products are formulated with the best of science and nature to deliver youthful and luminous-looking skin. Our clinically

More information

EPIDUO GEL PRODUCT INFORMATION

EPIDUO GEL PRODUCT INFORMATION EPIDUO GEL PRODUCT INFORMATION NAME OF THE MEDICINE EPIDUO Topical gel: 0.1% adapalene + 2.5% benzoyl peroxide Common Names: Adapalene and benzoyl peroxide Chemical Name : - Adapalene: 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic

More information

ROSACEA. Marie Piantino

ROSACEA. Marie Piantino ROSACEA Marie Piantino WHAT IS ROSACEA? Rosacea is disorder involving chronic inflammation of the cheeks, nose, chin, forehead, or eyelids; it may cause redness, vascularity (increased prominence of the

More information

Informed Consent For Facial Rejuvenation/Collagen Remodel

Informed Consent For Facial Rejuvenation/Collagen Remodel Informed Consent For Facial Rejuvenation/Collagen Remodel Client s name: Date: I authorize SilkySkin Laser Centers to perform the laser procedure. You will be treated with the Cynosure Elite TM laser,

More information

` National Unit Specification: General Information

` National Unit Specification: General Information ` National Unit Specification: General Information NUMBER D05R 12 COURSE This is a free standing unit which may be used as part of a Scottish Group Award or be associated with other programmes of study

More information

Literature Scan: Topical Antiparasitics

Literature Scan: Topical Antiparasitics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Brilliant Bodywork. Name: Date: Address: City: State: Zip: Home Phone: Business Phone: Cell Phone: Date of Birth: address:

Brilliant Bodywork. Name: Date: Address: City: State: Zip: Home Phone: Business Phone: Cell Phone: Date of Birth:  address: Brilliant Bodywork Skin Care History Questionnaire and Waiver Please answer the following questions so that your Skin Care Specialist may have a better understanding of your general health and lifestyle,

More information

New Zealand Datasheet

New Zealand Datasheet New Zealand Datasheet 1 PRODUCT NAME Epiduo 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Adapalene 0.1% / benzoyl peroxide 2.5% gel 3 PHARMACEUTICAL FORM Epiduo is a white to very pale yellow opaque gel

More information

5504 Backlick Road Springfield, Virginia

5504 Backlick Road Springfield, Virginia Name: Address: Phone: City: Zip Code: Cell: Phone: Text Cell Phone email How did you hear about us: General Health State: Contact me by 1. Rate your level of stress: (5 = highest, 1= lowest) 5 4 3 2 1

More information

An Investigation into the Anti-aging Efficacy of a Serum Containing a Red Mangrove Extract

An Investigation into the Anti-aging Efficacy of a Serum Containing a Red Mangrove Extract 10-2013 English Edition International Journal for Applied Science Personal Care Detergents Specialties Dr. O. Hevia An Investigation into the Anti-aging Efficacy of a Serum Containing a Red Mangrove Extract

More information

The CARI Guidelines Caring for Australians with Renal Impairment. 12. Prophylaxis for exit site/tunnel infections using mupirocin

The CARI Guidelines Caring for Australians with Renal Impairment. 12. Prophylaxis for exit site/tunnel infections using mupirocin 12. Prophylaxis for exit site/tunnel infections using mupirocin Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) Prophylactic

More information

Colour and lighten hair

Colour and lighten hair Colour and lighten hair UHB73 Learner name: SVQ Learner number: VTCT is the specialist awarding organisation for the Hairdressing, Beauty Therapy, Complementary Therapy, Hospitality and Catering and Sport

More information

Mme. Maharaj School of Cosmetology & Hair. Train to become a Professional Cosmetologist

Mme. Maharaj School of Cosmetology & Hair. Train to become a Professional Cosmetologist Mme. Maharaj School of Cosmetology & Hair Designs Train to become a Professional Cosmetologist TRAIN TO BECOME A PROFESSIONAL COSMETOLOGIST Full-time: Monday - Thursday 9:00am - 3:00pm Part-time: Saturdays

More information

Hair Removal Using a Combination of Electrical and Optical Energies Multiple Treatments Clinical Study Six Months Follow up

Hair Removal Using a Combination of Electrical and Optical Energies Multiple Treatments Clinical Study Six Months Follow up Hair Removal Using a Combination of Electrical and Optical Energies Multiple Treatments Clinical Study Six Months Follow up Antonio Del Giglio M.D., James Shaoul M.D. Introduction In the past decade, intense

More information

INFLUENCE OF FASHION BLOGGERS ON THE PURCHASE DECISIONS OF INDIAN INTERNET USERS-AN EXPLORATORY STUDY

INFLUENCE OF FASHION BLOGGERS ON THE PURCHASE DECISIONS OF INDIAN INTERNET USERS-AN EXPLORATORY STUDY INFLUENCE OF FASHION BLOGGERS ON THE PURCHASE DECISIONS OF INDIAN INTERNET USERS-AN EXPLORATORY STUDY 1 NAMESH MALAROUT, 2 DASHARATHRAJ K SHETTY 1 Scholar, Manipal Institute of Technology, Manipal University,

More information

NEWS RELEASE. CONTACTS: Investors: Lisa DeFrancesco (862) Media: Mark Marmur (862) Ember Garrett (714)

NEWS RELEASE. CONTACTS: Investors: Lisa DeFrancesco (862) Media: Mark Marmur (862) Ember Garrett (714) NEWS RELEASE CONTACTS: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 Ember Garrett (714) 246-3525 JUVÉDERM VOLBELLA XC APPROVED BY U.S. FDA FOR USE IN LIPS AND PERIORAL RHYTIDS

More information

Imbue Aesthetics & Wellness PATIENT REGISTRATION FORM

Imbue Aesthetics & Wellness PATIENT REGISTRATION FORM Today's Date Legal Name Marital Status Sex DOB Age Mailing Address Preferred Phone Number Email Do we have your permission to add you to our email list to receive newsletters and promotions? YES NO Emergency

More information

NZQA registered unit standard 2889 version 5 Page 1 of 5

NZQA registered unit standard 2889 version 5 Page 1 of 5 Page 1 of 5 Title Bleach and tone hair Level 4 Credits 10 Purpose This unit standard is for learners in the hairdressing industry who have knowledge and ability in hair colour selection and application

More information

BARNET CORNEOTHERAPY RESURFACID CR. AHA s Normalization of Increased Skin s ph Time Release Technology Ultra Mild Exfoliation

BARNET CORNEOTHERAPY RESURFACID CR. AHA s Normalization of Increased Skin s ph Time Release Technology Ultra Mild Exfoliation BARNET CORNEOTHERAPY RESURFACID CR AHA s Normalization of Increased Skin s ph Time Release Technology Ultra Mild Exfoliation The information contained in this technical bulletin is, to the best of our

More information

ISOTREX GEL Isotretinoin 0.05% w/w

ISOTREX GEL Isotretinoin 0.05% w/w ISOTREX GEL Isotretinoin 0.05% w/w Consumer Medicine Information What is in this leaflet Please read this leaflet carefully before you use Isotrex Gel. This leaflet answers some common questions about

More information

Chapter III Part- I: Consumers perception toward cosmeceuticals Introduction Characteristics of Indian consumer behavior

Chapter III Part- I: Consumers perception toward cosmeceuticals Introduction Characteristics of Indian consumer behavior Understanding perception of consumers and dermatologists is essential part of pharmaceutical and cosmetic business strategy. Whereas to understand perception of pharmaceutical and cosmetic companies view

More information

Hyalurosmooth. by Beauty Creations. Natural fine line and wrinkle filler

Hyalurosmooth. by Beauty Creations. Natural fine line and wrinkle filler Hyalurosmooth by Beauty Creations Natural fine line and wrinkle filler Hyalurosmooth Botanical alternative to hyaluronic acid Smoothing and filling of fine lines and wrinkles by injecting «fillers» such

More information

CONSUMER MEDICINE INFORMATION

CONSUMER MEDICINE INFORMATION CONSUMER MEDICINE INFORMATION ACZONE (dapsone 7.5% w/w) topical gel January 2017 V 1.0 1 ACZONE gel (dapsone 7.5% w/w) Consumer Medicine Information What is in this leaflet This leaflet answers some common

More information

ITEC Unit 695 Creatively Colour and Lighten Hair

ITEC Unit 695 Creatively Colour and Lighten Hair ITEC Unit 695 Creatively Colour and Lighten Hair What this unit is about: This unit is about combining, adapting and personalising a range of colouring and lightening techniques to achieve a variety of

More information

REPORT OF INSTRUMENTAL TEST AFTER 30 DAYS OF PRODUCT APPLICATION

REPORT OF INSTRUMENTAL TEST AFTER 30 DAYS OF PRODUCT APPLICATION Client: NATURA LABORATORIJI D. O. O. POD JELŠAMI 12 1290 GROSUPLJE SLOVENIJA Sample (according to declaration of the Client) 1. TESTED PRODUCT: HAIR INHIBITOR 2. COMPARATIVE PRODUCT: INHIBITIF Received

More information

To acclimate skin to AHAs prior to a peel Anti-aging, exfoliation, builds collagen. Gentle cleanser to remove sebum, skin debris and makeup.

To acclimate skin to AHAs prior to a peel Anti-aging, exfoliation, builds collagen. Gentle cleanser to remove sebum, skin debris and makeup. Glycolic Acid Peels and Effective Home Care Products Rejuvenate and Complement the Benefits of Injectable Fillers and Botulinum Toxin Type A in the Treatment of Photoaged David Wrone, MD, Colleen J. Crane,

More information

Hair colour correction services

Hair colour correction services Hair colour correction services The aim of this unit is to develop your knowledge, understanding and the skills necessary to determine and correct more complex colouring problems. To achieve this unit,

More information

Massey Medical. Medical History (Dermal Filler) MEDICAL INFORMATION: I am interested in the following services: Juvederm: Botox:

Massey Medical. Medical History (Dermal Filler) MEDICAL INFORMATION: I am interested in the following services: Juvederm: Botox: Medical History (Dermal Filler) Name: Date: _ Date of Birth: Phone: _ MEDICAL INFORMATION: I am interested in the following services: Juvederm: Botox: NO YES Allergies history of severe allergy or anaphylaxis.

More information

University of Wisconsin-Madison Hazard Communication Standard Policy Dept. of Environment, Health & Safety Office of Chemical Safety

University of Wisconsin-Madison Hazard Communication Standard Policy Dept. of Environment, Health & Safety Office of Chemical Safety University of Wisconsin-Madison Hazard Communication Standard Policy Dept. of Environment, Health & Safety Office of Chemical Safety 1.0 Introduction... 1 1.1 Purpose... 1 1.2 Regulatory Background...

More information

Rodan + Fields Dermatologists Skincare Changing skin and changing lives. The Perfect Partnership

Rodan + Fields Dermatologists Skincare Changing skin and changing lives. The Perfect Partnership Rodan + Fields Dermatologists Skincare Changing skin and changing lives The Perfect Partnership Why partnering with Rodan + Fields is the right choice Services currently provides: Hair Services Hair Removal

More information

SALIBIAN MOSSI. Name Last First Middle. Address Apt. City State Zip. Home Phone Cell Phone Work Phone. Address

SALIBIAN MOSSI. Name Last First Middle. Address Apt. City State Zip. Home Phone Cell Phone Work Phone.  Address Name Last First Middle Address Apt. City State Zip Home Phone Cell Phone Work Phone Email Address Age Date of Birth Sex Height Weight Marital Status Drivers License # Social Security # Employer Occupation

More information

EpiCeram Topical therapeutic Skin Barrier Emulsion

EpiCeram Topical therapeutic Skin Barrier Emulsion EpiCeram Topical therapeutic Skin Barrier Emulsion PEDIAPHARM INC. Date of preparation: August 31, 2010 Summary Product Information: EpiCeram Skin Barrier Emulsion is a steroid-free, fragrance - free,

More information

Prospective Patient Application

Prospective Patient Application Prospective Patient Application Mission Statement: The ISHRS recognizes the impact of hair loss due to trauma or disease on a person s well being. The mission of Operation Restore is to facilitate hair

More information

Laser Skin Resurfacing what to expect

Laser Skin Resurfacing what to expect Laser Skin Resurfacing what to expect Laser skin resurfacing is a treatment to reduce facial wrinkles and skin irregularities, such as blemishes or acne scars. The technique directs short, concentrated

More information